Page last updated: 2024-12-06

vecuronium bromide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Vecuronium bromide is a non-depolarizing neuromuscular blocking agent that acts by competitively inhibiting acetylcholine at the neuromuscular junction. It is synthesized by a multi-step process starting from the natural alkaloid, steroidal sapogenin. Vecuronium bromide is used primarily as a muscle relaxant during anesthesia, particularly for intubation and surgery. It is also used for the management of mechanically ventilated patients with tetanus, malignant hyperthermia, and other conditions involving muscle spasms. Its study is important due to its widespread use in clinical settings, the need to understand its mechanism of action, and to investigate potential side effects and drug interactions. '

Vecuronium Bromide: Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

vecuronium bromide : The organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium substituents. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID39764
CHEMBL ID1200629
CHEBI ID9940
SCHEMBL ID22250
MeSH IDM0022572

Synonyms (114)

Synonym
bromide, vecuronium
hydrobromide, vecuronium
V0120
vecuronium bromide
norcuron
einecs 256-723-9
piperidinium, 1-(3-alpha,17-beta-diacetoxy-2-beta-piperidino-5-alpha-androstan-16-beta-yl)-1-methyl-, bromide
piperidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl)-1-methyl-, bromide
5alpha-androstan-3alpha,17beta-diol, 16beta-pipecolinio-2beta-piperidino-,bromide,diacetate
org nc 45
nc-45
bromuro de vecuronio [inn-spanish]
1-(3alpha,17beta-dihydroxy-2beta-piperidino-5alpha-androstan-16beta,5alpha-yl)-1-methylpiperidinium bromide, diacetate
vecuronium hydrobromide
vecuronii bromidum [inn-latin]
org-nc 45
bromure de vecuronium [inn-french]
smr000471625
MLS001424317
norcuron (tn)
D00767
50700-72-6
vecuronium bromide (jan/usp/inn)
NCGC00167467-01
(2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane bromide
AC-2000
HMS2052I21
pancuronium bromide impurity, vecuronium bromide -
CHEMBL1200629
nsc-759184
AKOS005145904
CHEBI:9940 ,
(2beta,3alpha,5alpha,16beta,17beta)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane bromide
bromure de vecuronium
1-[3alpha,17beta-bis(acetoxy)-2beta-(1-piperidinyl)-5alpha-androstan-16beta-yl]-1-methylpiperidinium bromide
bromuro de vecuronio
vecuronii bromidum
AKOS007930694
cas-50700-72-6
tox21_112471
dtxsid1023736 ,
dtxcid003736
vecronium bromide
1-(3,17-diacetoxy-2-piperidino-5-androstan-16-yl)-1-methylpiperidinium bromide
(+)-1-(3,17-diacetoxy-2-piperidino-5-androstan-16-yl)-1-methylpiperidinium bromide
CCG-101147
vecuronium bromide [usan:usp:inn:ban:jan]
unii-7e4php5n1d
nsc 759184
7e4php5n1d ,
vecuronium bromide [jan]
vecuronium bromide [vandf]
vecuronium bromide [usp-rs]
pancuronium bromide impurity d [ep impurity]
vecuronium bromide [who-dd]
vecuronium bromide [mi]
vecuronium bromide [mart.]
vecuronium bromide [ep monograph]
piperidinium, 1-((2.beta.,3.alpha.,5.alpha.,16.beta.,17.beta.)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl)-1-methyl-, bromide
vecuronium bromide [usp monograph]
pancuronium bromide impurity, vecuronium bromide - [usp impurity]
vecuronium bromide [ep impurity]
vecuronium bromide [inn]
vecuronium bromide [usan]
vecuronium bromide [orange book]
musculax
vecuronium (bromide)
HY-B0118A
CS-1881
NC00397
SCHEMBL22250
NCGC00167467-03
tox21_112471_1
1-[(2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl]-1-methylpiperidinium bromide hydrate
Q-101014
vecuronium for system suitability, european pharmacopoeia (ep) reference standard
1-((2s,3s,5s,8r,9s,10s,13s,14s,16s,17r)-3,17-diacetoxy-10,13-dimethyl-2-(piperidin-1-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-16-yl)-1-methylpiperidin-1-ium bromide
1-[(2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl]-1-methylpiperidinium bromide
mfcd00867762
[(2s,3s,5s,8r,9s,10s,13s,14s,16s,17r)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate;bromide
SR-01000763634-3
sr-01000763634
vecuronium bromide, united states pharmacopeia (usp) reference standard
vecuronium for peak identification, european pharmacopoeia (ep) reference standard
vecuronium bromide, pharmaceutical secondary standard; certified reference material
vecuronium bromide, european pharmacopoeia (ep) reference standard
HMS3715L15
BCP06528
[(2s,3s,10s,13s,16s,17r)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate;bromide
Z1541759894
S1405
DS-12625
Q27108523
1-[(1r,2s,3as,3br,5as,7s,8s,9as,9bs,11as)-1,7-bis(acetyloxy)-9a,11a-dimethyl-8-(piperidin-1-yl)-hexadecahydro-1h-cyclopenta[a]phenanthren-2-yl]-1-methylpiperidin-1-ium bromide
EN300-122368
HMS3884C15
1-((2s,3s,5s,10s,13s,16s,17r)-3,17-diacetoxy-10,13-dimethyl-2-(piperidin-1-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-16-yl)-1-methylpiperidin-1-ium bromide
1-((2s,3s,5s,10s,13s,16s,17r)-3,17-diacetoxy-10,13-dimethyl-2-(piperidin-1-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-16-yl)-1-methylpiperidin-1-iumbromide
vecuronium for system suitability
vecuronium bromide (ep impurity)
vecuronium bromide (mart.)
vecuronium bromide (usan:usp:inn:ban:jan)
vecuronio bromuro
vacuronium
vecuronii bromidum (inn-latin)
pancuronium bromide impurity d (ep impurity)
vecuronium bromide (usp-rs)
bromure de vecuronium (inn-french)
pancuronium bromide impurity, vecuronium bromide-(usp impurity)
vecuronium bromide (ep monograph)
vecuronium bromide (usp monograph)
bromuro de vecuronio (inn-spanish)
m03ac03
1-(3alpha,17beta-bis(acetoxy)-2beta-(1-piperidinyl)-5alpha-androstan-16beta-yl)-1-methylpiperidinium bromide

Research Excerpts

Overview

Vecuronium bromide is a non-depolarizing neuromuscular blocking agent with a rather low therapeutic level.

ExcerptReferenceRelevance
"Vecuronium bromide is a non-depolarizing neuromuscular blocking agent with a rather low therapeutic level. "( Determination of vecuronium in blood by HPLC with UV and electrochemical detection: a pilot study in man.
Chou, CH; Ho, ST; Ho, W; Hu, OY, 1991
)
1.72

Effects

ExcerptReferenceRelevance
"Vecuronium bromide (Norcuron) has been used as an intubation and surgical muscle relaxant besides the use of different types of anaesthesia in the course of 230 gynaecological operations. "( Observations with norcuron (pharmaceutical works of Gedeon Richter, Budapest, Hungary) injection.
Fister, T, 1990
)
1.72

Toxicity

ExcerptReferenceRelevance
"To determine which of atracurium or vecuronium is associated with fewer adverse cardiovascular and pulmonary events in high-risk patients, the authors administered these drugs to patients with known asthma."( Atracurium versus vecuronium in asthmatic patients. A blinded, randomized comparison of adverse events.
Caldwell, JE; Fisher, DM; Lau, M, 1995
)
0.29
"1 mg/kg vecuronium over 5-10 s, and a blinded observer recorded cardiovascular, pulmonary, and cutaneous signs of adverse reactions for 6 min."( Atracurium versus vecuronium in asthmatic patients. A blinded, randomized comparison of adverse events.
Caldwell, JE; Fisher, DM; Lau, M, 1995
)
0.29
" The incidence of noncardiovascular adverse events (increase in peak airway pressure > 5 cmH2O, tidal volume decrease > 10%, rashes, and wheezing) did not differ between atracurium (17%) and vecuronium (7%)."( Atracurium versus vecuronium in asthmatic patients. A blinded, randomized comparison of adverse events.
Caldwell, JE; Fisher, DM; Lau, M, 1995
)
0.29
"The authors conclude that, in patients with asthma, adverse cardiovascular events are more common with atracurium than with vecuronium."( Atracurium versus vecuronium in asthmatic patients. A blinded, randomized comparison of adverse events.
Caldwell, JE; Fisher, DM; Lau, M, 1995
)
0.29
"Rocuronium is as safe and efficacious as vecuronium for CIP in the pediatric ED."( Safety and efficacy of rocuronium for controlled intubation with paralytics in the pediatric emergency department.
Abramo, TJ; Goto, CS; Mendez, DR; Wiebe, RA, 2001
)
0.31
" Atropine and diazepam in the premedication, propofol and fentanyl during induction, muscle relaxation facilitation by vecuronium, and sevoflurane or isoflurane for maintenance seem to be a safe general anesthetic choice for analgesic intolerant patients with and without asthma."( General anesthesia and postoperative pain management in analgesic intolerant patients with/without asthma: is it safe?
Basgül, E; Bozkurt, B; Celiker, V; Kalyoncu, AF; Karakaya, G; Oguzalp, H,
)
0.13
" We hypothesized that the Food and Drug Administration Adverse Event Reporting System could be used to confirm whether there has been an unusual incidence of anaphylactic events for rocuronium in the United States (U."( The risk of anaphylactic reactions to rocuronium in the United States is comparable to that of vecuronium: an analysis of food and drug administration reporting of adverse events.
Bhananker, SM; Bishop, MJ; O'Donnell, JT; Salemi, JR, 2005
)
0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" The use of the basophil activation marker CD63 as a screening tool in selecting a safe muscle relaxant is presented."( Anaphylaxis to vecuronium: the use of basophil CD63 expression as a possible screening tool to identify a safe alternative.
Appadurai, IR; Sudheer, PS, 2007
)
0.34
"No serious adverse events (AEs) were reported."( Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers.
Cammu, G; De Kam, PJ; Decoopman, M; Demeyer, I; Foubert, L; Peeters, PA; Smeets, JM, 2008
)
0.35
" Two reviewers independently selected the trials; extracted data on reversal times, incomplete reversals of NMB, and adverse events (AEs); and assessed the trials' methodological quality and evidence level."( Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials.
Carron, M; Ori, C; Tellaroli, P; Zarantonello, F, 2016
)
0.43
" No serious adverse effects were happened in this study."( Safety, tolerability, and pharmacokinetics of adamgammadex sodium, a novel agent to reverse the action of rocuronium and vecuronium, in healthy volunteers.
Jiang, Y; Liu, J; Xiang, S; Zhang, W; Zhang, Y; Zhao, W, 2020
)
0.56
" Specifically, this study assessed the impact of sugammadex on cardiac adverse events (AEs) and other prespecified AEs of clinical interest."( A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants.
Blobner, M; Broussard, DM; Herring, WJ; Lin, L; Lombard, JF; Lutkiewicz, J; Mukai, Y; Wang, A; Watkins, M, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
"kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups."( Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient.
Diaz, J; Halevy, JD; Matteo, RS; Ornstein, E; Schwartz, AE, 1992
)
0.28
" In combination with data from subfractionation studies the results indicate that the pharmacokinetic analysis of the hepatic disposition of steroidal muscle relaxants may be used to evaluate actual transport phenomena participating in the hepatic disposition of these drugs."( Pharmacokinetics of steroidal muscle relaxants in isolated perfused rat liver.
Meijer, DK; Mol, WE; Oosting, R; Paanakker, JE; Rombout, F; Scaf, AH, 1992
)
0.28
" All other pharmacodynamic parameters were similar."( A comparison of the pharmacodynamics of rocuronium and vecuronium during halothane anaesthesia.
Baird, WL; Booth, MG; Bryden, FM; Marsh, B; Robertson, EN, 1992
)
0.28
" In cats with renal failure, 3-desacetylvecuronium pharmacokinetic and pharmacodynamic variables did not differ from those in control cats."( Pharmacokinetics, neuromuscular effects, and biodisposition of 3-desacetylvecuronium (Org 7268) in cats.
Agoston, S; Caldwell, JE; Gruenke, LD; Khuenl-Brady, KS; Miller, RD; Segredo, V; Sharma, ML; Shin, YS, 1991
)
0.28
" Pharmacokinetic parameters of these drugs were obtained by using two-compartment open model and population pharmacokinetics."( [Effects of prostaglandin E1 on vecuronium and fentanyl pharmacokinetics in humans].
Ishii, T; Johno, I; Moriyama, S, 1991
)
0.28
" With ORG 9616, mean elimination half-life was slower and mean residence time longer in cats with renal pedicle ligation."( The neuromuscular blocking effects and pharmacokinetics of ORG 9426 and ORG 9616 in the cat.
Agoston, S; Caldwell, JE; Canfell, PC; Castagnoli, KP; Khuenl-Brady, K; Miller, RD, 1990
)
0.28
" The pharmacokinetic parameters of pipecuronium were compared with those of pancuronium (0."( [Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man].
Hanaoka, K; Kushida, Y; Murakami, S; Numata, K; Sugai, N; Yajima, C; Yamamoto, K; Yamamura, H, 1990
)
0.51
" Due to the high variability of individual responses to the same dosing scheme the design of drug administration regimens is often based on the average pharmacokinetic parameters of a data base of individuals."( Approximate maximum likelihood population pharmacokinetic models for the design of dosage regimens.
Lago, PJ, 1989
)
0.28
" Cumulative dose response curves for vecuronium and the pharmacodynamic variables measured were similar with both anaesthetic agents."( Lack of effects of emulsified propofol ('Diprivan') on vecuronium pharmacodynamics--preliminary results in man.
Booij, LH; Crul, JF; De Grood, PM; Van Beem, HB; Van De Wetering, M; Van Egmond, J, 1985
)
0.27
"The authors used pharmacokinetic and pharmacodynamic modeling to explain the time course of neuromuscular blockade following single or multiple doses of three nondepolarizing muscle relaxants."( A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants.
Fisher, DM; Rosen, JI, 1986
)
0.27
" The pharmacodynamic differences observed might be due to the varying acetylcholine receptor density of the muscle groups studied."( [The pharmacodynamics of vecuronium on the musculature of the vocal cords and the ball of the thumb. Preliminary report].
Draxler, V; Gilly, H; Redl, G; Streinzer, W; Zrunek, M, 1986
)
0.27
" For pancuronium, there were no statistically significant differences between groups for these pharmacokinetic or pharmacodynamic parameters."( Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults.
Castagnoli, KP; Fisher, DM; Miller, RD; Rupp, SM, 1987
)
0.27
" This increased duration may be related to both a decreased plasma clearance and a prolonged elimination half-life of vecuronium in the renal failure group."( The pharmacodynamics and pharmacokinetics of vecuronium in patients anesthetized with isoflurane with normal renal function or with renal failure.
Arden, J; Caldwell, J; Canfell, PC; Castagnoli, KP; Cronnelly, R; Lynam, DP; Miller, RD, 1988
)
0.27
" The pharmacokinetics could be described using a two-compartment open model with a distribution half-life of approximately 4 min and an elimination half-life of approximately 31 min."( Pharmacokinetics and pharmacodynamics of Org NC 45 in man.
Bencini, A; van der Veen, F, 1980
)
0.26
" The serum concentration of Org NC 45 was determined by normal-phase high performance liquid chromatography (sensitivity 50 ng ml-1), and a two-compartment open pharmacokinetic model was fitted to resulting data."( Pharmacokinetics of Org NC45 (norcuron) in patients with and without renal failure.
Fahey, MR; Miller, RD; Morris, RB; Nguyen, TL; Upton, RA, 1981
)
0.26
"The pharmacodynamic behaviour upon continuous infusion and bolus administration of pancuronium and vecuronium was studied in cats with and without ligated renal pedicles."( Pharmacodynamics of vecuronium and pancuronium in cats with and without ligated renal pedicles.
Booij, LH; Crul, JF; Van de Pol, F; Vree, TB, 1982
)
0.26
" Data were analyzed by nonlinear regression and fit to a three-compartment pharmacokinetic model and a four-compartment pharmacodynamic model."( Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans.
Castagnoli, N; Cronnelly, R; Fisher, DM; Gencarelli, P; Miller, RD; Nguyen-Gruenke, L, 1983
)
0.27
"Vecuronium and pancuronium were compared for placental transfer, pharmacokinetic variables, and neonatal effects during cesarean section under general anesthesia."( Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section.
Abboud, TK; Baysinger, CL; Dailey, PA; Fisher, DM; Kim, KC; Miller, RD; Shinohara, Y; Shnider, SM, 1984
)
0.27
" Between groups no differences in onset time, clinical duration, and pharmacokinetic variables were found."( Pharmacodynamics, pharmacokinetics, and intubation conditions after priming with three different doses of vecuronium.
Gilly, H; Huemer, G; Lackner, F; Plainer, B; Schwarz, S; Weindlmayr-Goettel, M, 1995
)
0.29
"The agreement between evoked adductor pollicis mechanomyogram and first dorsal interosseous evoked electromyogram (EMG) was evaluated during a pharmacodynamic study of rocuronium and vecuronium."( The agreement between adductor pollicis mechanomyogram and first dorsal interosseous electromyogram. A pharmacodynamic study of rocuronium and vecuronium.
Engbaek, J; Hangaard, N; Roed, J; Viby-Mogensen, J, 1994
)
0.29
" The authors used a pharmacodynamic model not requiring muscle relaxant plasma concentrations to reconcile these findings."( Comparison of twitch depression of the adductor pollicis and the respiratory muscles. Pharmacodynamic modeling without plasma concentrations.
Bragg, P; Donati, F; Fisher, DM; Lau, M; Meistelman, C; Sheiner, LB; Shi, J, 1994
)
0.29
"The pharmacodynamic model is based on the traditional model, in which: (1) vecuronium concentration at the neuromuscular junction (C(effect)) is a function of the plasma concentration versus time curve and a rate constant for equilibration between plasma and the neuromuscular junction (k(eo)); and (2) effect is a function of C(effect), the steady-state plasma concentration that produces 50% effect (C50), and a factor to explain the sigmoid relationship between concentration and effect."( Comparison of twitch depression of the adductor pollicis and the respiratory muscles. Pharmacodynamic modeling without plasma concentrations.
Bragg, P; Donati, F; Fisher, DM; Lau, M; Meistelman, C; Sheiner, LB; Shi, J, 1994
)
0.29
"min-1, was infused for 10 min, venous blood sampled for 60 min, and twitch tension and plasma concentration data were used to determine pharmacodynamic variables in each patient."( Mild intraoperative hypothermia does not change the pharmacodynamics (concentration-effect relationship) of vecuronium in humans.
Caldwell, JE; Gruenke, LD; Heier, T; Miller, RD; Sharma, ML, 1994
)
0.29
" Pharmacokinetic simulations suggest that vecuronium's cumulation occurs as recovery shifts from distribution to elimination whereas atracurium's recovery always occurs during elimination."( Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study.
Fisher, DM; Gruenke, L; Hart, P; Lau, M; Sharma, ML; Wright, PM, 1994
)
0.29
" Plasma was sampled for 128 min to determine muscle relaxant concentrations; pharmacodynamic modeling was used to determine effect-compartment drug concentrations (Ce)."( Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study.
Fisher, DM; Gruenke, L; Hart, P; Lau, M; Sharma, ML; Wright, PM, 1994
)
0.29
" Atracurium's recovery phase half-life was 14."( Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study.
Fisher, DM; Gruenke, L; Hart, P; Lau, M; Sharma, ML; Wright, PM, 1994
)
0.29
"34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes."( Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade.
Hartvig, P; Nilsson, A; Persson, PM; Wessén, A,
)
0.13
"We could not show any statistically significant influence of an epidural blockade on the pharmacokinetic parameters of propofol."( Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade.
Hartvig, P; Nilsson, A; Persson, PM; Wessén, A,
)
0.13
"kg-1; a longer terminal elimination half-life 116 (44-672) vs."( The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers.
Caldwell, JE; Fisher, DM; Gruenke, LD; McLoughlin, C; Miller, RD; Segredo, V; Sharma, ML; Szenohradszky, J; Wright, PM, 1994
)
0.29
" Terminal half-life and mean residence time were 71."( Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent.
Proost, JH; Smeulers, NJ; van den Broek, L; Wierda, JM, 1994
)
0.29
" Derived compartmental pharmacokinetic and pharmacokinetic-pharmacodynamic parameters were similar to those obtained noncompartmentally with complete sampling every 10 sec, because back-extrapolation to time zero contributed to the increase in the AUC."( Importance of early blood sampling on vecuronium pharmacokinetic and pharmacodynamic parameters.
Bevan, DR; Donati, F; Ducharme, J; Varin, F, 1993
)
0.29
" It is concluded that renal function is likely involved in the pharmacokinetic parameters of vecuronium."( Pharmacodynamics of vecuronium in patients with and without renal failure: a meta-analysis.
Beauvoir, C; D'Athis, F; Daures, JP; Peray, P; Peschaud, JL, 1993
)
0.29
" A reduced clearance and prolonged elimination half-life of pancuronium and vecuronium have been demonstrated."( The pharmacokinetics of rocuronium bromide in hepatic cirrhosis.
Hunter, JM, 1995
)
0.29
" The current study investigates the pharmacokinetic or pharmacodynamic mechanisms responsible for this observation."( Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients.
Alloul, K; Ebrahim, Z; Shutway, F; Varin, F; Whalley, DG, 1996
)
0.29
" Plasma vecuronium concentrations were fitted to a two-compartment pharmacokinetic model, and the effect compartment equilibration rate constant was derived with a nonparametric link model."( Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients.
Alloul, K; Ebrahim, Z; Shutway, F; Varin, F; Whalley, DG, 1996
)
0.29
"The twofold increase in clearance provides evidence of a pharmacokinetic origin to the carbamazepine-vecuronium interaction; however, the possibility of a concurrent pharmacodynamic alteration cannot be assessed."( Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients.
Alloul, K; Ebrahim, Z; Shutway, F; Varin, F; Whalley, DG, 1996
)
0.29
" A pharmacokinetic model accounting for the presence and potency of vecuronium's 3-desacetyl metabolite and a sigmoid e-max pharmacodynamic model were fit to the resulting plasma concentration and effect (adductor pollicis and laryngeal adductors) data to determine relative sensitivities and rates of equilibration between plasma and effect site concentrations."( Pharmacodynamic modeling of vecuronium-induced twitch depression. Rapid plasma-effect site equilibration explains faster onset at resistant laryngeal muscles than at the adductor pollicis.
Brown, R; Fisher, DM; Lau, M; Sharma, M; Szenohradszky, J; Wright, PM, 1997
)
0.3
"The traditional approach to pharmacokinetic/ pharmacodynamic modeling of muscle relaxants requires sampling of plasma to determine drug concentrations."( Are plasma concentration values necessary for pharmacodynamic modeling of muscle relaxants?
Fisher, DM; Wright, PM, 1997
)
0.3
" Various pharmacokinetic models accounting for the presence and potency of vecuronium's 3-desacetyl metabolite and a sigmoid e-max pharmacodynamic model were fit to the resulting plasma concentration and effect (adductor pollicis and laryngeal adductors) data to determine IR50 keo, and gamma for each effect."( Are plasma concentration values necessary for pharmacodynamic modeling of muscle relaxants?
Fisher, DM; Wright, PM, 1997
)
0.3
"Certain pharmacodynamic parameters were estimated accurately in the absence of plasma concentration values."( Are plasma concentration values necessary for pharmacodynamic modeling of muscle relaxants?
Fisher, DM; Wright, PM, 1997
)
0.3
" The elimination half-life was 50."( Pharmacokinetics of vecuronium during acute isovolaemic haemodilution.
Li, L; Liao, X; Liu, JH; Luo, LK; Tong, SY; Xue, FS; Zou, Q, 1997
)
0.3
" Using a multicompartment model and sequential dosing, the authors studied the ability of tests to determine most pharmacokinetic and pharmacodynamic parameters of vecuronium without measuring plasma concentrations."( Pharmacokinetic analysis of the effect of vecuronium in surgical patients: pharmacokinetic and pharmacodynamic modeling without plasma concentrations.
Graham, GG; Torda, TA; Warwick, NR, 1998
)
0.3
"After sequential doses, measurement of the time course of the effect of vecuronium yields pharmacokinetic and pharmacodynamic parameters with clinically acceptable accuracy in individual patients."( Pharmacokinetic analysis of the effect of vecuronium in surgical patients: pharmacokinetic and pharmacodynamic modeling without plasma concentrations.
Graham, GG; Torda, TA; Warwick, NR, 1998
)
0.3
" The pharmacokinetic differences may be related to the differences in the sensitivity to vecuronium between genders."( The pharmacokinetics of vecuronium in male and female patients.
An, G; Liao, X; Luo, LK; Xue, FS; Zou, Q, 1998
)
0.3
" A pharmacokinetic model was fitted to these plasma concentration data, and its parameters permitted to vary between the periods to determine if they had altered."( Do the pharmacokinetics of vecuronium change during prolonged administration in critically ill patients?
Caldwell, JE; Gruenke, LD; Miller, RD; Segredo, V; Sharma, ML; Wright, PM, 1998
)
0.3
" To determine whether similar differences exist for rapacuronium, a muscle relaxant with rapid onset and offset, the authors determined its pharmacodynamic characteristics."( A pharmacodynamic explanation for the rapid onset/offset of rapacuronium bromide.
Brown, R; Fisher, DM; Lau, M; Wright, PM, 1999
)
0.3
" A semiparametric effect compartment pharmacodynamic model was fit to values for rapacuronium plasma concentrations and twitch tension of the adductor pollicis and laryngeal adductors."( A pharmacodynamic explanation for the rapid onset/offset of rapacuronium bromide.
Brown, R; Fisher, DM; Lau, M; Wright, PM, 1999
)
0.3
" Pharmacokinetic parameters were determined using mixed-effects modeling."( Influence of renal failure on the pharmacokinetics and neuromuscular effects of a single dose of rapacuronium bromide.
Brown, R; Caldwell, JE; Fisher, DM; Lau, M; Luks, AM; Szenohradszky, J; Wright, PM, 1999
)
0.3
" The scientific and educational literature has used analogs of pharmacokinetic phenomena to make the concepts more intuitive."( Hydraulic analog for simultaneous representation of pharmacokinetics and pharmacodynamics: application to vecuronium.
Nikkelen, E; Ohrn, MA; van Meurs, WL, 1998
)
0.3
"To determine the hemodynamic and pharmacodynamic effects of rapid bolus administration of cisatracurium compared with vecuronium."( A two-center study evaluating the hemodynamic and pharmacodynamic effects of cisatracurium and vecuronium in patients undergoing coronary artery bypass surgery.
Cannon, JE; Carrier, M; Dupont, C; Gagnon, L; Rosenbloom, M; Roy, M; Searle, NR; Thomson, I, 1999
)
0.3
" In this study, the pharmacokinetic behavior (n = 7) of this metabolite and the pharmacokinetic/pharmacodynamic (PK/PD) relationship of rapacuronium (n = 10) and Org 9488 (n = 7) were investigated in humans."( Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488).
Proost, JH; Schiere, S; Schuringa, M; Wierda, JM, 1999
)
0.3
" As part of a study to determine its neuromuscular effects, the authors sampled plasma sparsely to determine the influence of age, gender, and other covariates on its pharmacokinetic characteristics."( Factors affecting the pharmacokinetic characteristics of rapacuronium.
Angst, MS; Bevan, D; Bikhazi, G; Fisher, DM; Fragen, RJ; Kahwaji, R; Matteo, RS; Ornstein, E, 1999
)
0.3
" Pharmacokinetic analysis was performed using a population approach (mixed-effects modeling) to determine the influence of demographic characteristics and preoperative laboratory values on the pharmacokinetic parameters."( Factors affecting the pharmacokinetic characteristics of rapacuronium.
Angst, MS; Bevan, D; Bikhazi, G; Fisher, DM; Fragen, RJ; Kahwaji, R; Matteo, RS; Ornstein, E, 1999
)
0.3
" Rapacuronium's weight-normalized pharmacokinetic parameters were not influenced by age, gender, or other covariates examined."( Factors affecting the pharmacokinetic characteristics of rapacuronium.
Angst, MS; Bevan, D; Bikhazi, G; Fisher, DM; Fragen, RJ; Kahwaji, R; Matteo, RS; Ornstein, E, 1999
)
0.3
" This finding contrasts to an age-related decrease in plasma clearance observed in a study of 10 healthy volunteers and in a pooled analysis of the pharmacokinetic data from 206 adults in multiple clinical studies."( Factors affecting the pharmacokinetic characteristics of rapacuronium.
Angst, MS; Bevan, D; Bikhazi, G; Fisher, DM; Fragen, RJ; Kahwaji, R; Matteo, RS; Ornstein, E, 1999
)
0.3
" Pipecuronium resembles pancuronium in its pharmacokinetic and neuromuscular blocking profile, but is devoid of cardiovascular effects."( Clinical pharmacokinetics of the newer neuromuscular blocking drugs.
Atherton, DP; Hunter, JM, 1999
)
0.3
" The plasma concentrations of vecuronium were determined with an improved fluorometry and the pharmacokinetic parameters were obtained by fitting the data with a 3P87 program."( [Effect of acute moderate isovolumic hemodilution on the pharmacokinetics of vecuronium].
An, G; Liu, Q; Luo, L; Xue, F; Zou, Q, 1997
)
0.3
" The elimination half-life was 88 (77-102) min in controls and 90 (76-117) min in patients with cirrhosis."( Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis.
Duvaldestin, P; Rebufat, Y; Slavov, V, 1999
)
0.3
" A three-compartment pharmacokinetic model was justified."( Antagonism of rapacuronium using edrophonium or neostigmine: pharmacodynamics and pharmacokinetics.
Danjoux, G; Hing, JP; Hunter, JM; Mills, KG; Pollard, BJ; Scott, JM; Wright, PM, 1999
)
0.3
" In the current study, the authors determined its pharmacokinetic characteristics in children."( Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration.
Brown, R; Fisher, DM; Hsu, J; Infosino, A; Reynolds, LM, 2000
)
0.31
" A mixed-effects population pharmacokinetic analysis was applied to these values to determine bioavailability, absorption rate constant, and time to peak plasma concentration with intramuscular administration."( Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration.
Brown, R; Fisher, DM; Hsu, J; Infosino, A; Reynolds, LM, 2000
)
0.31
"To determine the effect of moderate and deep hypothermic cardiopulmonary bypass (CPB) on the pharmacokinetic and pharmacodynamic behaviour of vecuronium in infants and children."( Vecuronium pharmacokinetics and pharmacodynamics during hypothermic cardiopulmonary bypass in infants and children.
Donati, F; Harris, J; Kulkarni, P; Menard, G; Varin, F; Withington, D, 2000
)
0.31
" Rapacuronium's pharmacokinetic parameters were determined using mixed-effects modeling."( Effect of renal failure and cirrhosis on the pharmacokinetics and neuromuscular effects of rapacuronium administered by bolus followed by infusion.
Abengochea, A; Atherton, DP; Brown, R; Dempsey, GA; Fisher, DM; Hunter, JM, 2000
)
0.31
" Pharmacokinetic variables were derived from plasma samples collected before and after administration of vecuronium."( Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy.
Greenblatt, DJ; Martyn, JA; Soriano, SG; Sullivan, LJ; Venkatakrishnan, K, 2001
)
0.31
"The rapid onset and offset of rapacuronium can be explained from its pharmacokinetic and pharmacodynamic characteristics."( A pharmacokinetic-dynamic explanation of the rapid onset-offset of rapacuronium.
Proost, JH; Wright, PM, 2001
)
0.31
"0 microg/ml, and the half-life may be longer than previously reported values in adult patients."( Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia.
Morikawa, N; Noguchi, T; Oishi, K; Takeyama, M, 2002
)
0.31
" Pharmacokinetic parameters do not appear to differ markedly in hepatic insufficiency, but clearance is reduced by approximately 30% in renal failure."( Pharmacokinetics and pharmacodynamics of rapacuronium bromide.
Wight, WJ; Wright, PM, 2002
)
0.31
" Pharmacokinetic and pharmacodynamic modeling was used to characterize the disposition of vecuronium and patient responses to it in the two groups."( Influence of chronic phenytoin administration on the pharmacokinetics and pharmacodynamics of vecuronium.
Caldwell, JE; McCarthy, G; Sharma, ML; Szenohradszky, J; Wright, PM, 2004
)
0.32
" Pharmacokinetic findings were compared with those from a previous study in infants after noncardiac major surgery."( Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates.
Anderson, BJ; Peters, JW; Simons, SH; Tibboel, D; Uges, DR, 2006
)
0.33
"To test the suitability of an Iterative Two-Stage Bayesian (ITSB) technique for population pharmacokinetic analysis of rich data sets, and to compare ITSB with Standard Two-Stage (STS) analysis and nonlinear Mixed Effect Modeling (MEM)."( Performance of an iterative two-stage bayesian technique for population pharmacokinetic analysis of rich data sets.
Eleveld, DJ; Proost, JH, 2006
)
0.33
"ITSB is a suitable technique for population pharmacokinetic analysis of rich data sets, and in the presented data set it is superior to STS and MEM."( Performance of an iterative two-stage bayesian technique for population pharmacokinetic analysis of rich data sets.
Eleveld, DJ; Proost, JH, 2006
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"0001), which yielded shorter elimination half-life for vecuronium (5."( Vecuronium pharmacokinetics in patients with major burns.
Han, TH; Kaneda, K; Vega-Villa, KR; Woo, S; Yamashita, S, 2014
)
0.4

Compound-Compound Interactions

ExcerptReferenceRelevance
" Compared to vecuronium, pancuronium increased heart rate, and protected from arterial hypotension, when combined with low-dose alfentanil."( Alfentanil combined with vecuronium or pancuronium: haemodynamic implications.
Oikkonen, M, 1992
)
0.28
"The usefulness of alfentanil for eye surgery, when combined with either vecuronium or pancuronium, was evaluated in 44 fit anticholinergized patients."( Alfentanil combined with vecuronium or pancuronium for use in eye surgery.
Oikkonen, MP, 1992
)
0.28
"To investigate the pharmacokinetics of propofol in combination with epidural anesthesia or with intravenous (i."( Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade.
Hartvig, P; Nilsson, A; Persson, PM; Wessén, A,
)
0.13
" In Group 1, a continuous infusion of propofol was combined with an epidural block with bupivacaine."( Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade.
Hartvig, P; Nilsson, A; Persson, PM; Wessén, A,
)
0.13
" Nevertheless, the concentration-time profile changed during infusion, rendering the described infusion regimen, in combination with epidural anesthesia, unsatisfactory for adequate hypnosis."( Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade.
Hartvig, P; Nilsson, A; Persson, PM; Wessén, A,
)
0.13
"To compare the hemodynamics and post-anesthetic recovery of total intravenous anesthesia (TIVA) with remifentanil or fentanyl combined with propofol administered by target controlled infusion (TCI) in neurosurgery."( [Remifentanil and fentanyl combined with propofol administered by target controlled infusion in neurosurgery].
Bai, N; Cheng, Z; Guo, Q; Wang, Y; Yang, S, 2009
)
0.35
"TIVA with remifentanil or fentanyl combined with propofol administered by TCI in neurosurgical operation can provided steadible hemodynamics."( [Remifentanil and fentanyl combined with propofol administered by target controlled infusion in neurosurgery].
Bai, N; Cheng, Z; Guo, Q; Wang, Y; Yang, S, 2009
)
0.35
"This thorough corrected QT (QTc) study evaluated the effect of sugammadex alone and in combination with rocuronium or vecuronium on the individually corrected QTc interval (QTcI)."( Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
de Kam, PJ; Peeters, P; Prohn, M; Thomsen, T; van Kuijk, J, 2010
)
0.36
"Based on the results of this study of healthy subjects, it can be concluded that sugammadex alone or in combination with rocuronium or vecuronium is not associated with QTc prolongation."( Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
de Kam, PJ; Peeters, P; Prohn, M; Thomsen, T; van Kuijk, J, 2010
)
0.36
" The present study was conducted in order to evaluate neuronal effects of SUG alone and in combination with both ROC and VEC."( Neuronal Effects of Sugammadex in combination with Rocuronium or Vecuronium.
Aldasoro, C; Aldasoro, M; Gimeno-Raga, M; Guerra-Ojeda, S; Iradi, A; Jorda, A; Marchio, P; Mauricio, MD; Obrador, E; Valles, SL; Vila, JM, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" These processes probably provide a protective mechanism limiting the overall rate of absorption as well as the bioavailability of potentially toxic organic amines."( Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption.
Meijer, DK; Müller, M; Schinkel, AH; Smit, JW; Weert, B, 1998
)
0.3
" A mixed-effects population pharmacokinetic analysis was applied to these values to determine bioavailability, absorption rate constant, and time to peak plasma concentration with intramuscular administration."( Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration.
Brown, R; Fisher, DM; Hsu, J; Infosino, A; Reynolds, LM, 2000
)
0.31
" Intramuscular bioavailability averaged 56%."( Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration.
Brown, R; Fisher, DM; Hsu, J; Infosino, A; Reynolds, LM, 2000
)
0.31
" After intramuscular administration, bioavailability is 56%, and plasma rapacuronium concentrations peak within 4 or 5 min."( Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration.
Brown, R; Fisher, DM; Hsu, J; Infosino, A; Reynolds, LM, 2000
)
0.31
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"We have studied the dose-response relationship for neostigmine in 36 adult (ages 18-50 yr) and 36 elderly (ages > 70 yr) subjects during antagonism of neuromuscular block induced by vecuronium."( Dose-response relationships for neostigmine antagonism of vecuronium-induced neuromuscular block in adults and the elderly.
Cooper, R; McCarthy, GJ; Mirakhur, RK; Stanley, JC, 1992
)
0.28
" Dose-response relationships were established for each substance alone and for combinations of vecuronium with its metabolites."( Antagonism of vecuronium by one of its metabolites in vitro.
Khuenl-Brady, KS; Koller, J; Mair, P, 1992
)
0.28
" From cumulative dose-response curves the ED50 and ED90 were calculated to be 175 and 300 micrograms/kg, respectively."( Dose-response relation, neuromuscular blocking action, intubation conditions, and cardiovascular effects of Org 9273, a new neuromuscular blocking agent.
Lambalk, LM; Richardson, FJ; van den Broek, L; Wierda, JM, 1991
)
0.28
" In addition, the block/fade relationships for cumulative dosing and sequential dilution were the same when measurements were made at steady-state for several doses."( Relationships between block-of-twitch and train-of-four fade in the mouse phrenic nerve-diaphragm preparation.
Rosenberg, H; Slomowitz, SA; Storella, RJ, 1991
)
0.28
" Neither cardiovascular side effects nor signs of histamine release occurred after the injection of both muscle relaxants at our dosage level."( [Comparative studies of atracurium and vecuronium for medium-length surgical procedures in infants and young children].
Grundmann, U; Ismaily, AJ; Kleinschmidt, S; Motsch, J, 1991
)
0.28
" Clinical information includes diagnoses, dosage of neuromuscular junction blocker, other medications affecting the neuromuscular system, and neuromuscular examination and clinical course."( Prolonged paralysis after treatment with neuromuscular junction blocking agents.
Balbierz, JM; Clemmer, TP; Gooch, JL; Petajan, JH; Suchyta, MR, 1991
)
0.28
" Maximum depression of the first response (T1) in the train-of-four was measured, and dose-response curves were constructed."( Nitrous oxide potentiates vecuronium neuromuscular blockade in humans.
Balendran, P; Bevan, DR; Donati, F; Fiset, P, 1991
)
0.28
" Before its introduction into clinical practice in the USA, in the first phase of this study the neuromuscular potency of pipecuronium was determined under "balanced" and enflurance anaesthesia by the cumulative log dose-response method in 30 patients each."( Neuromuscular and cardiovascular effects of pipecuronium.
Duncalf, D; Foldes, FF; Goldiner, PL; Nagashima, H; Nguyen, HD, 1990
)
0.28
" Other 191 patients were divided into three groups according to the type and dosage of pretreatment as follows: VB 20 micrograms."( [Influence of small doses of vecuronium and pancuronium on succinylcholine-induced neuromuscular blockade].
Nishizawa, M, 1990
)
0.28
" The aim of this study was to investigate the dose-response relationship of alcuronium and to compare the time course of its neuromuscular effects with vecuronium following intubation doses of both compounds."( [The dose-response relationship and time course of the neuromuscular blockade by alcuronium].
Adler, R; Agoston, S; Khünl-Brady, KS; Koller, J; Mair, P; Mitterschiffthaler, G; Pühringer, F, 1990
)
0.28
" The relative cutaneous histamine-releasing ability of each drug was derived from calculated dose-response relationships."( Comparative cutaneous histamine release by neuromuscular blocking agents.
Galletly, DC, 1986
)
0.27
"The effect of vecuronium on the heart rate response to atropine has been studied by comparing dose-response relationships in two groups of patients who underwent extracorporeal shock wave lithotripsy."( Effect of vecuronium on atropine-induced changes in heart rate.
Gaylard, DG; Lim, M; Ridley, S, 1989
)
0.28
" In its simplest form only global descriptors of the response to a bolus are used to obtain the dosing scheme leading to the desired drug plasma concentration level."( Approximate maximum likelihood population pharmacokinetic models for the design of dosage regimens.
Lago, PJ, 1989
)
0.28
"To determine the potencies of edrophonium and neostigmine as antagonists of nondepolarizing neuromuscular blockade produced by atracurium and vecuronium, dose-response curves were constructed for both antagonists when given at 10% spontaneous recovery of first twitch height."( Dose-response relationships for edrophonium and neostigmine as antagonists of atracurium and vecuronium neuromuscular blockade.
Bevan, DR; Donati, F; Smith, CE, 1989
)
0.28
" Prior administration of succinylcholine was associated with a leftward shift of dose-response curve of vecuronium or pancuronium."( [The effect of succinylcholine on vecuronium and pancuronium].
Kosaka, F; Manabe, N; Morita, K; Ohta, Y; Ono, K, 1989
)
0.28
" Cumulative vecuronium dose-response curves were determined for both muscles in 11 ASA class I adult patients."( Relative potency of vecuronium on the diaphragm and the adductor pollicis.
Chauvin, M; Duvaldestin, P; Guirimand, F; Lebrault, C, 1989
)
0.28
" We conclude that there is no clinical indication that the dosage of atracurium and vecuronium during inhalation anesthesia should be reduced, but the doses of pipecuronium and pancuronium should be reduced when prolonged paralysis is not desired."( Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics.
Agoston, S; Hermans, J; Ket, JM; Koot, HW; Rashkovsky, OM; Swen, J, 1989
)
0.28
"The purpose of this study was to compare the incremental, cumulative dose method and the single bolus injection technique for construction of dose-response curves for vecuronium."( Dose-response curves for vecuronium during halothane and neurolept anaesthesia: single bolus versus cumulative method.
Engbaek, J; Ording, H; Skovgaard, LT; Viby-Mogensen, J, 1985
)
0.27
"To evaluate possible potentiation of neuromuscular blocking effect of a combination of vecuronium and d-tubocurarine, cumulative dose-response curves were constructed to compare the potency of this combination with vecuronium and d-tubocurarine given alone."( Vecuronium and d-tubocurarine combination: potentiation of effect.
Ferres, CJ; Gibson, FM; Mirakhur, RK, 1985
)
0.27
" With reduced dosage and with careful neuromuscular monitoring, vecuronium can be used safely in the myasthenic patient."( Vecuronium in the myasthenic patient.
Bell, CF; Florence, AM; Hunter, JM; Jones, RS; Utting, JE, 1985
)
0.27
" The sizes of the bolus injections were based on previously determined cumulative dose-response relationships."( Neuromuscular blocking effects of atracurium, vecuronium and pancuronium during bolus and infusion administration.
Gramstad, L; Lilleaasen, P, 1985
)
0.27
" The dose-response curve for vecuronium was determined after the injection of a single bolus (40, 55 or 70 micrograms kg-1) to 33 patients."( Clinical pharmacology of vecuronium in children. Studies during nitrous oxide and halothane in oxygen anaesthesia.
da Silva, GL; Delleur, MM; Loose, JP; Meistelman, C; Saint-Maurice, C, 1986
)
0.27
"25 mg/kg) during anesthesia with O2/N2O/fentanyl, to generate dose-response curves for the relaxants."( The effect of phenytoin on the magnitude and duration of neuromuscular block following atracurium or vecuronium.
Diaz, J; Matteo, RS; Ornstein, E; Schwartz, AE; Silverberg, PA; Young, WL, 1987
)
0.27
" In order to simulate clinical practice--which entails long-term oral treatment and significant reductions in systolic blood pressure--CA were administered to rats orally (by gavage) for 8 days at a dosage that induced a systolic blood pressure decrease of not more than 25 +/- 5 mmHg."( [Atracurium and vecuronium: interaction with three orally administered calcium antagonists in animal experiments].
Dozier, SE; Fulfer, RT; Ilias, WK; Williams, CH, 1987
)
0.27
"The effect of age on the log-based cumulative dose-response curve of vecuronium was determined in ten age groups of 80 pediatric patients ranging from neonates to adolescents during thiopental-fentanyl-N2O/O2 anesthesia."( Age-dependence of the dose-response curve of vecuronium in pediatric patients during balanced anesthesia.
Meretoja, OA; Neuvonen, PJ; Wirtavuori, K, 1988
)
0.27
" The evoked compound EMG, additionally recorded in one patient, reflected almost the same dose-response relationship as twitch tension, yet the EMG recovered faster than the twitch."( Muscle relaxation in patients with Duchenne's muscular dystrophy. Use of vecuronium in two patients.
Buzello, W; Huttarsch, H, 1988
)
0.27
" Although the time to maximum NMB following divided doses of pancuronium, atracurium or vecuronium is significantly longer than that for succinylcholine, divided dosing significantly decreases the time required to reach maximal NMB."( Accelerated onset of non-depolarizing neuromuscular blocking drugs: pancuronium, atracurium and vecuronium. A comparison with succinylcholine.
Gergis, SD; Mehta, MP; Sokoll, MD, 1988
)
0.27
"The ability of cumulative dose-response techniques to obtain accurate data is most likely limited by redistribution and elimination of the drug during the study period."( Cumulative dose-response with infusion: a technique to determine neuromuscular blocking potency of atracurium and vecuronium.
Bevan, DR; Donati, F; Smith, CE, 1988
)
0.27
" These simulations allow the user to contrast the time-course of relaxation to be expected with various dosage regimens."( Simulating the time-course of clinical paralysis.
Shanks, CA, 1988
)
0.27
" Cumulative dose responses studied in six cats showed that the NC 45 dosage required to produce 85--95% tibialis block was slightly greater than controls during respiratory and metabolic alkalosis."( Effects of changes in acid-base balance on neuromuscular blockade produced by ORG-NC 45.
Crul, JF; Funk, DI; Pol, FM, 1980
)
0.26
" The dose-response relationships for the antagonism of Org NC 45 and pancuronium neuromuscular blockades were not significantly different."( Antagonism of org NC 45 (vecuronium) and pancuronium neuromuscular blockade by neostigmine.
Gencarelli, PJ; Miller, RD, 1982
)
0.26
"The potencies of atracurium, Org NC 45 and pancuronium were determined using cumulative dose-response curves."( Dose-response relation for atracurium, ORG NC 45 and pancuronium.
Gramstad, L; Lilleaasen, P, 1982
)
0.26
"To compare two methods of estimating the potency of neuromuscular relaxants of medium duration, the authors determined the potency of vecuronium (ORG NC45) using cumulative dose-response (CDR) techniques, and compared these data with published values from our group obtained using the single bolus technique."( Potency determination for vecuronium (ORG NC45): comparison of cumulative and single-dose techniques.
Cronnelly, R; Fahey, MR; Fisher, DM; Miller, RD, 1982
)
0.26
" They then compared these dose-response relationships with values obtained for adults (greater than 18 years old) under comparable anesthetic conditions."( Neuromuscular effects of vecuronium (ORG NC45) in infants and children during N2O, halothane anesthesia.
Fisher, DM; Miller, RD, 1983
)
0.27
" and an infusion (150 micrograms kg-1 min-1 for 30 min and 75 micrograms kg-1 min-1 thereafter) on the pharmacodynamics and dose-response curves of atracurium and vecuronium were studied in 52 healthy (ASA I or II) patients."( Some effects of diisopropyl phenol (ICI 35 868) on the pharmacodynamics of atracurium and vecuronium in anaesthetized man.
Booij, LH; Crul, JF; Fragen, RJ; Robertson, EN; van Egmond, J, 1983
)
0.27
" Ten adolescents and ten children were given 20 micrograms/kg incremental doses of vecuronium to establish a cumulative dose-response curve during train-of-four stimulation."( Safety and efficacy of vecuronium in adolescents and children.
Gionfriddo, M; Goudsouzian, NG; Liu, LM; Martyn, JJ, 1983
)
0.27
"The dose-response curves of vecuronium and pancuronium were compared during ketamine anaesthesia in 60 patients (ASA I)."( Dose-response relationships and neuromuscular blocking effects of vecuronium pancuronium during ketamine anaesthesia.
Engbaek, J; Ording, H; Pedersen, T; Viby-Mogensen, J, 1984
)
0.27
" Atracurium also does not depend on hepatic function for metabolism; however, vecuronium may require dosing adjustments in hepatic disease."( Atracurium and vecuronium: two unique neuromuscular blocking agents.
Conner, CS, 1984
)
0.27
" The dose-response curves for the three groups did not differ from each other and no potentiation was demonstrated."( Dose-response studies with pancuronium, vecuronium and their combination.
Clarke, RS; Ferres, CJ; Gibson, FM; Mirakhur, RK; Pandit, SK, 1984
)
0.27
" We compared the dose-response and recovery pharmacodynamics of a new intermediate-acting NMB drug, cisatracurium besylate, to the intermediate-acting NMB drug, vecuronium (VEC), in a prospective, randomized, double-blind, multicenter study in critically ill adults."( Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients.
Bowton, DL; Cardenas, VJ; Casale, EJ; Coursin, DB; Ford, SR; Howard, D; Murray, MJ; Prielipp, RC; Scuderi, PE; Vender, J, 1995
)
0.29
"The dose-response relationship for edrophonium during antagonism of vecuronium-induced neuromuscular blockade was studied in two groups of adult patients of mean (SD) age 35 (10."( Dose-responses for edrophonium during antagonism of vecuronium block in young and older adult patients.
Maddineni, VR; McCarthy, GJ; McCoy, EP; Mirakhur, RK, 1995
)
0.29
" We studied the dose-response relationships of each drug and their combination with rocuronium in 200 ASA I or II patients during propofol-fentanyl-nitrous oxide-oxygen anaesthesia."( Comparative potency of steroidal neuromuscular blocking drugs and isobolographic analysis of the interaction between rocuronium and other aminosteroids.
Bakhamees, HS; el-Bakry, AK; Magboul, MA; Naguib, M; Samarkandi, AH, 1995
)
0.29
" First, we determined the effect of pretreatment with magnesium on the potency of vecuronium using a single bolus dose-response technique."( Interaction of magnesium sulphate with vecuronium-induced neuromuscular block.
Borgeat, A; Fuchs-Buder, T; Tassonyi, E; Wilder-Smith, OH, 1995
)
0.29
" The dose-response curves for neostigmine (10, 20, 30, and 40 micrograms/kg) were constructed using the TOFR values at 5-11 min, from which the ED50 values (a neostigmine dose required for a TOFR value of 50%) were derived."( Inadequate antagonism of vecuronium-induced neuromuscular block by neostigmine during sevoflurane or isoflurane anesthesia.
Fujita, T; Morita, T; Saito, S; Sato, H; Sugaya, T; Tsukagoshi, H, 1995
)
0.29
" The first 30 patients were randomized to receive either atracurium or vecuronium to create individual dose-response curves for these muscle relaxants."( Potency and maintenance requirement of atracurium and vecuronium given alone or together.
Erkola, O; Meretoja, OA; Rautoma, P, 1995
)
0.29
" The duration of action and recovery time from 75% to 25% block were longer than those produced by twice the dosage of vecuronium (62."( [A comparison between neuromuscular blocking effects of pipecuronium and vecuronium; a double blind controlled study in collaboration with 5 departments of anesthesiology].
Amaki, Y; Hanaoka, K; Hashimoto, Y; Kobayashi, T; Suzuki, H; Yamamura, H, 1994
)
0.29
" These guidelines recommend clinical indications for these agents and dosing ranges reflecting current medical opinion."( The role of nondepolarizing neuromuscular blocking agents in mechanically ventilated patients.
May, JR; Rutkowski, AF, 1994
)
0.29
" An individual dose-response curve of the atracurium-vecuronium combination was determined for every patient and its potency compared with that of the parent agents alone."( Synergism between atracurium and vecuronium in infants and children during nitrous oxide-oxygen-alfentanil anaesthesia.
Jalkanen, L; Meretoja, OA; Taivainen, T; Wirtavuori, K, 1994
)
0.29
" In eight subjects, vecuronium bolus dose potency was determined using a two-dose dose-response technique; the vecuronium infusion dose requirement to achieve 85% twitch depression also was determined."( The magnitude and time course of vecuronium potentiation by desflurane versus isoflurane.
Brown, R; Fisher, DM; Gruenke, L; Hart, P; Lau, M; Sharma, ML; Wright, PM, 1995
)
0.29
" This new system offers certain advantages over computer-controlled systems described previously for continuous infusion of muscle relaxants--that is, the option to choose either of two muscle relaxants to be infused and the inclusion of monitors to provide feedback about the dosage needed to produce a target level of neuromuscular blockade."( A versatile, computer-controlled, closed-loop system for continuous infusion of muscle relaxants.
Assef, SJ; Behrens, TL; Burke, MJ; Jones, KA; Lennon, RL, 1993
)
0.29
" The dose-response curves were determined by probit analysis."( Isobolographic and dose-response analysis of the interaction between pipecuronium and vecuronium.
Abdulatif, M; Naguib, M, 1993
)
0.29
" We found that atracurium was prescribed for 68% of study patients; 68% of the patients did not have renal, hepatic, or cardiovascular disease; dosages of NNMBAs varied; a statistically significant increase in dosage requirements over time occurred with atracurium; assessment of neuromuscular blockade was 100% subjective; and 41% and 17% of patients receiving atracurium and vecuronium, respectively, experienced prolonged neuromuscular weakness documented subjectively."( A retrospective analysis of long-term use of nondepolarizing neuromuscular blocking agents in the intensive care unit, and guidelines for drug selection.
Clarens, DM; Gilliland, SS; Kelly, KJ; Kohls, PK; Nahum, A; Vance-Bryan, K,
)
0.13
" Dose-response curve (DRC) constructed from log-probit transformation for the group not receiving nitrous oxide was shifted to the right by 12."( [Potentiation by nitrous oxide of vecuronium neuromuscular blockade measured by EMG].
Tsuchiya, A, 1994
)
0.29
"The dose-response relationship for vecuronium during anesthesia with the azeotropic mixture of halothane and diethyl ether (HE) (66 ml of halothane mixed with 34 ml of ether in the same bottle)/oxygen was compared with halothane/nitrous oxide/oxygen anesthesia."( Halothane-diethyl ether azeotrope anesthesia under primitive conditions: guidelines for neuromuscular blockade with vecuronium.
Bengtsson, M; Eriksson, LI; Kalman, SH; Lennmarken, C, 1993
)
0.29
"We have determined the cumulative dose-response relationship for vecuronium from the evoked compound electromyogram of the hypothenar muscles in eight patients who were receiving carbamazepine."( Influence of carbamazepine on the dose-response relationship of vecuronium.
Ebrahim, Z; Whalley, DG, 1994
)
0.29
" We constructed dose-response curves for vecuronium in 54 patients."( The effects of sevoflurane are similar to those of isoflurane on the neuromuscular block produced by vecuronium.
Fujita, T; Morita, T; Sugaya, T; Tsukagoshi, H; Yoshikawa, D, 1994
)
0.29
"These results indicate that crossover dosing of nondepolarizing muscle relaxants may have synergistic effects."( The effect of d-tubocurarine priming on an ED95 dose of vecuronium bromide.
Barlow, IK; Dombrowski, DL; Miguel, RV,
)
0.38
"The dose-response relationship and the time course of action of Org 7617, a short acting non-depolarizing neuromuscular blocking agent, were evaluated during thiopentone, fentanyl, halothane and N2O anaesthesia."( Clinical pharmacology of ORG 7617, a short-acting non-depolarizing neuromuscular blocking agent.
Agoston, S; Hommes, FD; Proost, JH; van den Broek, L; Wierda, JM, 1994
)
0.29
" After induction of anaesthesia with thiopentone and maintenance with N2O/O2 and fentanyl, vecuronium was administered to determine cumulative dose-response curves."( Pharmacodynamic behaviour of vecuronium in primary hyperparathyroidism.
Eurin, BG; Roland, EJ; Roupie, E; Wierda, JM, 1994
)
0.29
"86 micrograms ml-1) or induction of anaesthesia a cumulative dose-response curve of vecuronium was established to achieve a 95% depression of the twitch response."( The effect of epidural bupivacaine on vecuronium-induced neuromuscular blockade in children.
Meretoja, OA; Rosenberg, PH; Taivainen, T, 1994
)
0.29
"To identify the best anthropometric predictor for duration of action of neuromuscular block and to propose a better dosing regimen for vecuronium in obese patients, we studied 67 female patients (body weight 45-126 kg) anesthetized with thiopental, fentanyl, droperidol, and nitrous oxide."( Anthropometric variables as predictors for duration of action of vecuronium-induced neuromuscular block.
Helbo-Hansen, HS; Kirkegaard-Nielsen, H; Severinsen, IK; Toft, P, 1994
)
0.29
" For groups 2 and 6, atracurium was administered at a dosage of 4 mg/kg of body weight, followed by a continuous infusion of 15 mg/kg/h."( Porphyrinogenic effects of atracurium, vecuronium, and pancuronium in a primed rat model.
Bach, A; Böhrer, H; Bolsen, K; Goerz, G; Kohl, B; Martin, E; Schmidt, H, 1994
)
0.29
" To assess whether this interaction is also observed with the depolarizing drug, decamethonium, the potency of decamethonium alone and decamethonium after vecuronium (10 micrograms/kg) were assessed using a cumulative dose-response technique in two groups of six healthy patients each."( Resistance to decamethonium neuromuscular block after prior administration of vecuronium.
Campkin, NT; Feldman, SA; Hood, JR, 1993
)
0.29
" To establish whether placental transfer of vecuronium used in the above dosage has any clinically detectable effect upon the newborn."( Vecuronium-thiopentone induction for emergency caesarean section under general anaesthesia.
Teviotdale, BM, 1993
)
0.29
"Cumulative dose-response curves were obtained for vecuronium in 10 patients anaesthetised with thiopentone, enflurane and nitrous oxide using adductor pollicis mechanomyography."( The effect of residual receptor occupancy on sensitivity to repeated vecuronium.
Campkin, NT; Fauvel, NJ; Feldman, SA; Hood, JR, 1993
)
0.29
" A cumulative log-probit dose-response curve of vecuronium was established."( The neuromuscular blocking effects of vecuronium during sevoflurane, halothane and balanced anaesthesia in children.
Meretoja, OA; Taivainen, T, 1995
)
0.29
" After obtaining individual dose-response curves, bolus doses of vecuronium were given to maintain neuromuscular block at 90-98% for 60 min."( Effect of smoking on dose requirements for vecuronium.
Rautoma, P; Teiriä, H; Yli-Hankala, A, 1996
)
0.29
" This study investigated whether (1) the relative responses of muscles is inverted between succinylcholine (SUX) and vecuronium (VEC), and (2) differences in dose-response or duration of action are related to the morphology of fibres, endplates and acetylcholine receptors (AChR) in muscles."( Duration of succinylcholine and vecuronium blockade but not potency correlates with the ratio of endplate size to fibre size in seven muscles in the goat.
Donati, F; Ibebunjo, C; Srikant, CB, 1996
)
0.29
"In goats during thiopentone anaesthesia, the evoked EMG response to indirect train-of-four stimulation was monitored and the cumulative dose-response curves and duration of action of SUX and VEC in the diaphragm, cricoary-tenoideus dorsalis, thyroarytenoideus, transversus abdominis, rectus abdominis, soleus and gastrocnemius muscles were determined and related to their fibre composition, fibre size, endplate size, endplate to fibre size ratio, AChR number or AChR density by regression analysis."( Duration of succinylcholine and vecuronium blockade but not potency correlates with the ratio of endplate size to fibre size in seven muscles in the goat.
Donati, F; Ibebunjo, C; Srikant, CB, 1996
)
0.29
"To assess the neuromuscular blocking effect of vecuronium in adult burn patients, to draw dose-response curves, to determine the ED 95 according to burn surface area, to analyze the time course of this pattern in order to recognize the development of a resistance according to the length of postinjury period."( [Resistance to vecuronium in burnt patients. Influence of the burnt surface on the effectiveness of the dose 95].
Badetti, C; Bernini, V; Manelli, JC; Pascal, L, 1996
)
0.29
" Dose-response curves were determined using the single dose method from only one predetermined dose of vecuronium per patient on each day of the study."( [Resistance to vecuronium in burnt patients. Influence of the burnt surface on the effectiveness of the dose 95].
Badetti, C; Bernini, V; Manelli, JC; Pascal, L, 1996
)
0.29
"A dose-response relationship study for edrophonium to examine the modification of volatile anaesthetics on reversal of vecuronium block."( Sevoflurane and isoflurane impair edrophonium reversal of vecuronium-induced neuromuscular block.
Fujita, T; Kurosaki, D; Morita, T; Saito, S; Sato, H; Sugaya, T; Tsukagoshi, H, 1996
)
0.29
" The 50% and 90% inhibitory concentrations (IC50, IC90) of Vb, d-Tc and SCh were determined form dose-response curves."( [Neuromuscular effects of vecuronium d-tubocurarine and succinylcholine in malnourished rat's diaphragm].
Tajiri, O, 1996
)
0.29
"Adjusting the dosage of vecuronium by peripheral nerve stimulation versus standard clinical dosing in critically ill patients reduces drug requirements to maintain a desired depth of paralysis and, on average, produces faster recovery of neuromuscular function."( Retrospective pharmacoeconomic evaluation of dosing vecuronium by peripheral nerve stimulation versus standard clinical assessment in critically ill patients.
Lai, K; Lulek, M; Petitta, A; Rudis, MI; Zarowitz, BJ,
)
0.13
"After obtaining written, informed consent and baseline neurologic examinations, patients were randomized to treatment, where dosing was individualized by peripheral nerve stimulation or standard clinical assessment."( A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients.
Angus, E; Hyzy, R; Peterson, E; Popovich, J; Rudis, MI; Sikora, CA; Zarowitz, BJ, 1997
)
0.3
"To evaluate the influence of acute isovolemic hemodilution on the dose-response and time course of action of vecuronium, we studied 60 adult patients with and without hemodilution during surgery."( The influence of acute normovolemic hemodilution on the dose-response and time course of action of vecuronium.
An, G; Li, L; Liao, X; Liu, JH; Luo, LK; Tong, SY; Xue, FS; Zhang, RJ, 1998
)
0.3
" A sensitivity analysis of the parameter estimation procedure confirms that the time of peak effect following a bolus and the dose-response curve are accurately reflected by the new model."( Pharmacokinetic-pharmacodynamic model for educational simulations.
Good, ML; Nikkelen, E; van Meurs, WL, 1998
)
0.3
"(1) To compare the dose-response relations of rocuronium and vecuronium in healthy adult patients anesthetized with nitrous oxide-oxygen-fentanyl-thiopental; and (2) to evaluate the time-course of action of two drugs following equipotent doses."( A comparative study of the dose-response and time course of action of rocuronium and vecuronium in anesthetized adult patients.
An, G; Liao, X; Liu, JH; Luo, LK; Tong, SY; Xue, FS; Zhang, RJ; Zhang, YM, 1998
)
0.3
" The dose-response relations of rocuronium and vecuronium were determined by the cumulative dose-response technique."( A comparative study of the dose-response and time course of action of rocuronium and vecuronium in anesthetized adult patients.
An, G; Liao, X; Liu, JH; Luo, LK; Tong, SY; Xue, FS; Zhang, RJ; Zhang, YM, 1998
)
0.3
" The cumulative dose-response curve of vecuronium was shifted to the left in a parallel fashion compared with that of rocuronium."( A comparative study of the dose-response and time course of action of rocuronium and vecuronium in anesthetized adult patients.
An, G; Liao, X; Liu, JH; Luo, LK; Tong, SY; Xue, FS; Zhang, RJ; Zhang, YM, 1998
)
0.3
"To determine the differences between men and women in the dose-response curve and the time-course of effect of vecuronium, we studied 60 adult patients (30 male and 30 female), ASA I, age 18-51 yr, undergoing elective plastic surgery."( Dose-response curve and time-course of effect of vecuronium in male and female patients.
An, G; Liao, X; Liu, JH; Luo, LK; Tong, SY; Xue, FS; Zhang, RJ; Zhang, YM, 1998
)
0.3
" A cumulative dose-response curve for vecuronium was constructed, and pupillary changes in response to various noxious stimuli were evaluated with concomitant recording of the Spectral-Edge-Frequency 90% (SEF90; the frequency below which 90 percent of the EEG power is located)."( Vecuronium dose requirement and pupillary response in a patient with olivopontocerebellar atrophy (OPCA).
Fukura, H; Goto, F; Kuroda, M; Morita, T; Saruki, N; Yoshikawa, D, 1998
)
0.3
"We compared the dose-response relationships of cisatracurium, mivacurium, atracurium, vecuronium and rocuronium and examined the interactions of cisatracurium with mivacurium, atracurium, vecuronium and rocuronium in humans by isobolographic and fractional analyses."( Neuromuscular interaction between cisatracurium and mivacurium, atracurium, vecuronium or rocuronium administered in combination.
Chon, SU; Chun, YS; Kim, KS; Suh, JK, 1998
)
0.3
" However, the decreased clearance of rapacuronium and its potent metabolite in renal failure suggests that repeated dosing of rapacuronium may lead to prolonged effects in patients with renal failure."( Influence of renal failure on the pharmacokinetics and neuromuscular effects of a single dose of rapacuronium bromide.
Brown, R; Caldwell, JE; Fisher, DM; Lau, M; Luks, AM; Szenohradszky, J; Wright, PM, 1999
)
0.3
" Under propofol anesthesia, the cumulative dose-response curves of vecuronium were shifted to the left when compared with control ED50 and the slope showed that propofol had potentiated the action of vecuronium."( [Propofol potentiates the neuromuscular blocking effects of vecuronium in man].
Adachi, H; Ohmi, Y; Satoh, T; Watanabe, K, 2000
)
0.31
" The ED50 of each neuromuscular blocker was determined from cumulative log dose-response regression lines (n = 14)."( Adenosine potentiation of neuromuscular blocking agents in guinea-pigs.
Dan, K; Foldes, FF; Kornak, P; Nagashima, H; Nitahara, K; Vizi, ES, 2000
)
0.31
" Low dosage must be employed and repeated administration avoided."( Is vecuronium toxicity abolished by hemodialysis? A case report.
Borsa, S; Pignataro, A; Pozzato, M; Quarello, F; Rollino, C; Vallero, A; Visetti, E, 2000
)
0.31
"A rigorous study of the dose-response relation of rapacuronium has, to our knowledge, yet to be performed."( Dose-response and onset/offset characteristics of rapacuronium.
Flores, F; Ghori, K; Klewicka, MM; Kopman, AF; Neuman, GG, 2000
)
0.31
" By dosing to maintain target twitch depression, recovery was not prolonged."( Effect of renal failure and cirrhosis on the pharmacokinetics and neuromuscular effects of rapacuronium administered by bolus followed by infusion.
Abengochea, A; Atherton, DP; Brown, R; Dempsey, GA; Fisher, DM; Hunter, JM, 2000
)
0.31
" Drug combinations containing equipotent concentrations of two agents were tested and dose-response curves were determined."( Isobolographic analysis of non-depolarising muscle relaxant interactions at their receptor site.
Dipp, NC; Fokt, RM; Kindler, CH; Paul, M; Yost, CS, 2002
)
0.31
" The dosage of vecuronium required to obtain satisfactory muscular blockade and cessation of spontaneous breathing efforts was more than 10-fold the normal one."( Resistance to vecuronium in a term neonate.
Agosti, A; Cergol, M; Runti, G; Sarti, A; Scarpa, R, 2002
)
0.31
" After calibration to 100% of baseline electromyographic response values using an EMG monitor, incremental doses of 5, 10 and 20 microg/kg of vecuronium were administrated to produce 95% neuromuscular blockade and to obtain a cumulative dose-response curve for each patient."( Is the degree of sensitivity to nondepolarizing muscle relaxants related to requirements for postoperative ventilation in patients with myasthenia gravis?
Goto, F; Hinohara, H; Kadoi, Y; Kunimoto, F; Niijima, A; Saito, S, 2004
)
0.32
" That information was used to estimate the mean potency for each individual by an alternative method based on prior knowledge of the slope of the dose-response curve."( [Interaction between vecuronium and atracurium revisited by adapting an alternative method].
Steinberg, D, 2004
)
0.32
" Dosage or duration of aminoglycosides use did not relate to SNHL."( Ototoxic drugs and sensorineural hearing loss following severe neonatal respiratory failure.
Cheung, PY; Etches, PC; Peliowski, A; Robertson, CM; Tyebkhan, JM, 2006
)
0.33
"9 is slow in overweight and obese patients when vecuronium is dosed on the basis of the patient's RBW."( Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients.
Masaki, G; Ogawa, S; Suzuki, T, 2006
)
0.33
" This study explored the dose-response relation of sugammadex given as a reversal agent at reappearance of the second muscle twitch after rocuronium- and vecuronium-induced block."( Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent.
Cammu, G; Demeyer, I; Hans, P; Heeringa, M; Morias, K; Suy, K; van Duijnhoven, WG, 2007
)
0.34
" A dose-response relation was observed with sugammadex for reversal of both rocuronium- and vecuronium-induced neuromuscular block."( Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent.
Cammu, G; Demeyer, I; Hans, P; Heeringa, M; Morias, K; Suy, K; van Duijnhoven, WG, 2007
)
0.34
" The dosage of enflurane used, the minimum effective concentration of enflurane in alveolar air (MACEnf) and the changes of heart rate (HR) as well as blood pressure (BP) in patients at different time points in the operational process were observed."( Effect of general anaesthesia with combination of acupuncture and enflurane applied in radical operation of laryngocarcinoma.
Dong, QL; Wang, GN, 2006
)
0.33
"As compared with those in the control group, in the tested group, both the MACEnf and the dosage of enflurane were reduced, with the difference between the two groups significant (P<0."( Effect of general anaesthesia with combination of acupuncture and enflurane applied in radical operation of laryngocarcinoma.
Dong, QL; Wang, GN, 2006
)
0.33
"The authors found no study comparing potency and duration of action of vecuronium and atracurium in healthy Chinese, so they compared the dose-response relations of vecuronium and atracurium in anesthetized Chinese adult patients and evaluated the time-course of action of two drugs following administration of equipotent doses."( Comparisons of the dose-response and recovery time course of vecuronium and atracurium in anesthetized chinese adult patients.
Li, CW; Li, P; Liao, X; Liu, KP; Liu, Y; Sun, HT; Xu, YC; Xue, FS, 2007
)
0.34
" The dose-response relations of vecuronium and atracurium were determined using the cumulative dose-response technique."( Comparisons of the dose-response and recovery time course of vecuronium and atracurium in anesthetized chinese adult patients.
Li, CW; Li, P; Liao, X; Liu, KP; Liu, Y; Sun, HT; Xu, YC; Xue, FS, 2007
)
0.34
"The cumulative dose-response curve of vecuronium was shifted to the left in a parallel fashion compared with that of atracurium."( Comparisons of the dose-response and recovery time course of vecuronium and atracurium in anesthetized chinese adult patients.
Li, CW; Li, P; Liao, X; Liu, KP; Liu, Y; Sun, HT; Xu, YC; Xue, FS, 2007
)
0.34
" Many studies have demonstrated a dose-response relationship with sugammadex for reversal of neuromuscular blockade in patients induced and maintained under propofol anesthesia."( A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
Claudius, C; Debaene, B; Duvaldestin, P; Heeringa, M; Klein, J; Kuizenga, K; Saldien, V; Servin, F, 2010
)
0.36
"We designed this randomized, open-label, dose-response trial to explore the dose-response relationship of sugammadex for the reversal of deep neuromuscular blockade induced by rocuronium or vecuronium under propofol-induced and sevoflurane-maintained anesthesia."( A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
Claudius, C; Debaene, B; Duvaldestin, P; Heeringa, M; Klein, J; Kuizenga, K; Saldien, V; Servin, F, 2010
)
0.36
" Some statisticians now consider this approach outmoded and assert that non-linear regression (NLR) is the preferred way to analyse sigmoidal dose-response relationships."( Determining the potency of neuromuscular blockers: are traditional methods flawed?
Kopman, AF; Lien, CA; Naguib, M, 2010
)
0.36
"We analysed raw data for succinylcholine, rocuronium, rapacuronium, and cisatracurium from previously published studies using both LRA and NLR to determine the ED(50) and ED(95) values and the respective slopes of the dose-response relationships."( Determining the potency of neuromuscular blockers: are traditional methods flawed?
Kopman, AF; Lien, CA; Naguib, M, 2010
)
0.36
"Sugammadex shows a dose-response relationship for reversal of neuromuscular block (NMB) during propofol anaesthesia."( Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship.
Demeyer, I; Gordon, M; Heeringa, M; Ingimarsson, J; Klarin, B; Pühringer, FK; Sparr, HJ; van Duijnhoven, W, 2010
)
0.36
" In the dose-response analysis, the 50% and 95% effective doses were lower for sevoflurane than for propofol in both muscles, although this did not reach statistical significance."( Neuromuscular blockade by vecuronium during induction with 5% sevoflurane or propofol.
Higa, K; Iwashita, K; Kusumoto, G; Nitahara, K; Shono, S; Sugi, Y, 2010
)
0.36
" The two dosing strategies were equally effective at maintaining a goal TOF response despite patients receiving a significantly lower daily dose of vecuronium in the intermittent-bolus group."( Continuous infusion versus intermittent bolus dosing of vecuronium in patients receiving therapeutic hypothermia after sudden cardiac arrest.
Gulbis, BE; Jurado, LV, 2011
)
0.37
" This occurs because of dosing choices for neuromuscular blocking agents and anticholinesterases as well as insensitivity of typically used monitors of depth of NMB."( Development and potential clinical impairment of ultra-short-acting neuromuscular blocking agents.
Lien, CA, 2011
)
0.37
" These findings prompt us to place optimal dosing guidelines so as to avoid overdosing and thus delay recovery and help to get the excellent outcome of the surgery."( Vecuronium and fentanyl requirement in abdominal surgery under combined epidural-general anaesthesia and general anaesthesia alone.
Ahmed, A; Hoq, MF; Hossain, M; Huda, MR; Rahman, MM; Rahman, MS; Yeasmeen, S, 2012
)
0.38
" The dosage of vecuronium bromide in the iMR imaging group was larger than in the control group, but not significantly."( Effects of intraoperative magnetic resonance imaging on the neuromuscular blockade of vecuronium bromide in neurosurgery.
Guo, Y; Sun, L; Zhang, H, 2013
)
0.97
" Since the dosing guidelines for the timing and dose of reversal agents are based on the TOF count derived from the TOF-Watch SX, a manually assessed TOF count may lead to inadequate dosing and/or premature administration of reversal agents."( Comparison of train-of-four count by anesthesia providers versus TOF-Watch® SX: a prospective cohort study.
Bhananker, SM; Cain, KC; Ramaiah, R; Sellers, BA; Thilen, SR; Treggiari, MM, 2015
)
0.42
"The dose-response relationship of drugs to reverse vecuronium-, rocuronium-, and cisatracurium-induced neuromuscular block (NMB) was evaluated in vitro (competition binding assays and urine analysis), ex vivo (n = 34; phrenic nerve hemidiaphragm preparation), and in vivo (n = 108; quadriceps femoris muscle of the rat)."( Comparative Effectiveness of Calabadion and Sugammadex to Reverse Non-depolarizing Neuromuscular-blocking Agents.
Ayata, C; Blobner, M; Diaz-Gil, D; Eikermann, M; Eikermann-Haerter, K; Foerster, U; Ganapati, S; Haerter, F; Isaacs, L; Moreno Duarte, I; Simons, JC; Zhang, B, 2015
)
0.42
" The goal of our study was to investigate the real-world practice pattern of dosing of neuromuscular blocking agents (NMBA), utilizing the amount of NMBA used during the course of a case, adjusted for patient weight and case duration, as a surrogate measure of depth of NMB."( Investigation of intraoperative dosing patterns of neuromuscular blocking agents.
Beutler, SS; Gimlich, R; Palsen, S; Urman, RD; Wu, A; Yang, HK, 2019
)
0.51
" However, the speed of recovery might be affected by the dose of the neuromuscular blocker administered, and by the dosing regimen of that dose."( Context-sensitive recovery of neuromuscular function from vecuronium in dogs: Effects of dose and dosing protocol.
Duran, V; Lorenzutti, AM; Martin-Flores, M; Nejamkin, P; Rosetti, V; Sakai, DM; Zarazaga, MP, 2019
)
0.51
"This randomized, double-blind trial evaluated sugammadex-mediated recovery time from rocuronium- or vecuronium-induced moderate (M-) or deep (D-) neuromuscular block in morbidly obese adults dosed by actual (ABW) or ideal body weight (IBW)."( Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trial.
Blobner, M; DeAngelis, M; Herring, WJ; Horrow, JC; Li, W; Lombard, J; Speek, M, 2021
)
0.62
"ABW-based sugammadex dosing yields faster reversal without re-curarization, supporting ABW-based sugammadex dosing in the morbidly obese, irrespective of the depth of neuromuscular block or NMBA used."( Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trial.
Blobner, M; DeAngelis, M; Herring, WJ; Horrow, JC; Li, W; Lombard, J; Speek, M, 2021
)
0.62
"To conduct a meta-analysis to compare different dosing scalars of sugammadex in a morbidly obese population for reversal of neuromuscular blockade (NMB)."( Appropriate dosing of sugammadex for reversal of rocuronium-/vecuronium-induced muscle relaxation in morbidly obese patients: a meta-analysis of randomized controlled trials.
Lee, M; Liao, JQ; Lin, TY; Lu, CW; Shih, D, 2022
)
0.72
"gov, Cochrane Central Register of Controlled Trials (CENTRAL) and Google Scholar were searched for relevant randomized controlled trials (RCTs) comparing lower-dose sugammadex using ideal body weight (IBW) or corrected body weight (CBW) as dosing scalars with standard-dose sugammadex based on total body weight (TBW) among morbidly obese people after NMB."( Appropriate dosing of sugammadex for reversal of rocuronium-/vecuronium-induced muscle relaxation in morbidly obese patients: a meta-analysis of randomized controlled trials.
Lee, M; Liao, JQ; Lin, TY; Lu, CW; Shih, D, 2022
)
0.72
" The reversal time was significantly longer in patients receiving sugammadex with dosing scalar based on IBW than in patients receiving sugammadex with dosing scalar based on TBW (mean difference 55."( Appropriate dosing of sugammadex for reversal of rocuronium-/vecuronium-induced muscle relaxation in morbidly obese patients: a meta-analysis of randomized controlled trials.
Lee, M; Liao, JQ; Lin, TY; Lu, CW; Shih, D, 2022
)
0.72
" Muscle relaxant effects were monitored in both groups using a muscle relaxant monitor (train of stimuli-Watch), the onset time, T1 and T2 recovery time, and muscle relaxant dosage of vecuronium were observed."( Comparison of the synergistic effects of sevoflurane and desflurane on muscle relaxant vecuronium in laparoscopic colon cancer surgery.
Song, Q; Wang, Y; Zhang, Q; Zhao, X, 2022
)
0.72
" There is, however, a paucity of data regarding its dosing profile in infants and children younger than 2 years."( Analysis of the factors contributing to residual weakness after sugammadex administration in pediatric patients under 2 years of age.
Cates, AC; Clifton, JC; Freundlich, RE; Lorinc, AN, 2024
)
1.44
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
nicotinic antagonistAn antagonist at the nicotinic cholinergic receptor.
neuromuscular agentA drug used for its actions on skeletal muscle.
muscle relaxantA drug used to produce muscle relaxation (excepting neuromuscular blocking agents). Its primary clinical and therapeutic use is the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. Also used for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
quaternary ammonium saltDerivatives of ammonium compounds, (NH4(+))Y(-), in which all four of the hydrogens bonded to nitrogen have been replaced with univalent (usually organyl) groups.
organic bromide salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency19.65530.002541.796015,848.9004AID1347395; AID1347397; AID1347398
estrogen nuclear receptor alphaHomo sapiens (human)Potency33.49150.000229.305416,493.5996AID743079
cytochrome P450 2D6Homo sapiens (human)Potency30.90080.00108.379861.1304AID1645840
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency26.60110.000627.21521,122.0200AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 2Homo sapiens (human)IC50 (µMol)3.50000.40003.10009.7000AID721751
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Multidrug and toxin extrusion protein 2Homo sapiens (human)IC50 (µMol)25.20000.16003.95718.6000AID721752
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Multidrug and toxin extrusion protein 1Homo sapiens (human)IC50 (µMol)1.90000.01002.765610.0000AID721754
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (72)

Processvia Protein(s)Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
amino acid import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-alpha-amino acid transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (41)

Processvia Protein(s)Taxonomy
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-amino acid transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
basolateral plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (54)

Assay IDTitleYearJournalArticle
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID721754Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID711656Inhibition of nAChR-mediated twitch response in mouse hemidiaphragm2012European journal of medicinal chemistry, Oct, Volume: 5616-morpholino quaternary ammonium steroidal derivatives as neuromuscular blocking agents: synthesis, biological evaluation and in silico probe of ligand-receptor interaction.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID721753Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID721752Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID721751Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,046)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990582 (28.45)18.7374
1990's898 (43.89)18.2507
2000's381 (18.62)29.6817
2010's152 (7.43)24.3611
2020's33 (1.61)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 68.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index68.76 (24.57)
Research Supply Index7.94 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index122.74 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (68.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials657 (30.56%)5.53%
Reviews83 (3.86%)6.00%
Case Studies326 (15.16%)4.05%
Observational9 (0.42%)0.25%
Other1,075 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (17)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Opioid-Free Shoulder Arthroplasty [NCT03540030]Phase 486 participants (Actual)Interventional2016-09-30Completed
A Phase 4 Randomized, Active-Comparator Controlled Trial to Study the Efficacy and Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuronium Bromide in Morbidly Obese Subjects [NCT03346070]Phase 4207 participants (Actual)Interventional2018-01-01Completed
A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuronium Bromide in American Society of Anesthesiologists (A [NCT03346057]Phase 4344 participants (Actual)Interventional2017-12-20Completed
Ventilation by Mask Before and After the Administration of Neuromuscular Blockade: a Non-inferiority Trial [NCT02237443]Phase 4210 participants (Actual)Interventional2014-08-31Completed
The Effect of Dexmedetomidine to Cognition of Geriatrics in Prolonged Surgery,A Randomized Controlled Study [NCT02123355]Phase 480 participants (Anticipated)Interventional2014-08-31Not yet recruiting
Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients -a Single-center, Randomized ,Double-blinded and Controlled Trial [NCT02134093]Phase 4120 participants (Anticipated)Interventional2014-07-31Not yet recruiting
Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome [NCT05658692]Phase 41,000 participants (Anticipated)Interventional2022-10-01Recruiting
The Effect of Transcutaneous Electric Acupoint Stimulation on the Quality of Early Recovery in Patients Undergoing Gynecological Laparoscopic Surgery: a Prospective, Randomized, Placebo-controlled Trial [NCT02619578]60 participants (Actual)Interventional2013-11-30Completed
Comparative Study of Org 9426 With Vecuronium Bromide (Phase III) [NCT00970762]Phase 390 participants (Actual)Interventional2003-02-28Completed
A Multicenter, Randomized, Parallel Group Comparative, Active-Controlled, Safety-assessor Blinded. Phase IIIa, Pivotal Trial in Adult Subjects Comparing Org 25969 With Neostigmine as Reversal Agent of a Neuromuscular Block Induced by Maintenance Dosing of [NCT00473694]Phase 3182 participants (Actual)Interventional2005-11-28Completed
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care [NCT01431326]3,520 participants (Actual)Observational2011-11-30Completed
Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements? [NCT03219294]Phase 4116 participants (Actual)Interventional2017-05-01Completed
A Perspective, Multicentre, Randomized,Blind Study of Residual Curarization Incidence in China [NCT01690338]Phase 46,090 participants (Anticipated)Interventional2012-10-31Recruiting
Comparison of the Effects of Vecuronium and Cisatracurium on Electrophysiologic Monitoring During Neurosurgery [NCT01690364]74 participants (Actual)Interventional2012-07-31Completed
A Multi-Center, Randomized, Open-Label, Prospective Bridging, Parallel Dose-Finding Trial Comparing Efficacy, Safety and Pharmacokinetics of 4 Doses of Org 25969 and Placebo Administered at Reappearance of T2 After Rocuronium or Vecuronium in Japanese and [NCT00552617]Phase 2100 participants (Actual)Interventional2005-09-20Completed
Intraoperative Lidocaine Infusion vs. Esmolol Infusion for Postoperative Analgesia in Laparoscopic Cholecystectomy: a Randomized Clinical Trial [NCT02327923]Phase 490 participants (Actual)Interventional2015-01-31Completed
Efficacy of Atracurium-vecuronium Combination in Patients Undergoing Laparoscopic Surgery:a Randomised Controlled Study [NCT03371953]Phase 448 participants (Anticipated)Interventional2017-12-20Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00473694 (11) [back to overview]Number of Participants Responsive Only to Tactile Stimulation After Anesthesia (Clinical Assessment of Level of Consciousness)
NCT00473694 (11) [back to overview]Number of Participants Experiencing General Muscle Weakness
NCT00473694 (11) [back to overview]Number of Participants Aroused With Minimal Stimulation After Anesthesia (Clinical Assessment of Level of Consciousness)
NCT00473694 (11) [back to overview]Number of Participants Able to Perform a 5-second Head Lift
NCT00473694 (11) [back to overview]Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Vecuronium
NCT00473694 (11) [back to overview]Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Rocuronium
NCT00473694 (11) [back to overview]Number of Participants Awake and Oriented After Anesthesia (Clinical Assessment of Level of Consciousness)
NCT00473694 (11) [back to overview]Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8 After Neuromuscular Block (NMB) Induced by Vecuronium
NCT00473694 (11) [back to overview]Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8 After Neuromuscular Block (NMB) Induced by Rocuronium
NCT00473694 (11) [back to overview]Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7 After Neuromuscular Block (NMB) Induced by Vecuronium
NCT00473694 (11) [back to overview]Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7 After Neuromuscular Block (NMB) Induced by Rocuronium
NCT00552617 (3) [back to overview]Time From Start of Administration of Sugammadex or Placebo to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9
NCT00552617 (3) [back to overview]Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.7
NCT00552617 (3) [back to overview]Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.8
NCT03219294 (1) [back to overview]Duration of Surgery
NCT03346057 (6) [back to overview]Percentage of Participants Experiencing an Event of Clinical Interest (ECI) Up To 7 Days After Administration of Study Intervention
NCT03346057 (6) [back to overview]Percentage of Participants With Treatment-Emergent Sinus Tachycardia Events
NCT03346057 (6) [back to overview]Percentage of Participants With Other Treatment-Emergent Cardiac Arrhythmia Events
NCT03346057 (6) [back to overview]Percentage of Participants Experiencing an Adverse Event (AE) Up To 7 Days After Administration of Study Intervention
NCT03346057 (6) [back to overview]Percentage of Participants Experiencing a Serious Adverse Event (SAE) Up To 7 Days After Administration of Study Intervention
NCT03346057 (6) [back to overview]Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events
NCT03346070 (11) [back to overview]Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events
NCT03346070 (11) [back to overview]Percentage of Participants With Treatment-Emergent Sinus Tachycardia Events
NCT03346070 (11) [back to overview]Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.7: Geometric Mean Analysis
NCT03346070 (11) [back to overview]Percentage of Participants Experiencing an Event of Clinical Interest (ECI) After Administration of Study Intervention
NCT03346070 (11) [back to overview]Time to Recovery (TTR) of Participant Train Of Four (TOF) Ratio to ≥0.9: Primary Kaplan-Meier Analysis
NCT03346070 (11) [back to overview]Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.9: Secondary Geometric Mean Analysis
NCT03346070 (11) [back to overview]Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.8: Geometric Mean Analysis
NCT03346070 (11) [back to overview]Percentage of Participants Experiencing a Serious Adverse Event (SAE) After Administration of Study Intervention
NCT03346070 (11) [back to overview]Percentage of Participants Experiencing an Adverse Event (AE) After Administration of Study Intervention
NCT03346070 (11) [back to overview]Percentage of Participants With Other Treatment-Emergent Cardiac Arrhythmia Events
NCT03346070 (11) [back to overview]Percentage of Participants With Prolonged (>10 Minutes) Time to Recovery (TTR) of the Train Of Four (TOF) Ratio to ≥0.9
NCT03540030 (16) [back to overview]Nausea
NCT03540030 (16) [back to overview]Nausea
NCT03540030 (16) [back to overview]Falls
NCT03540030 (16) [back to overview]Falls
NCT03540030 (16) [back to overview]Constipation
NCT03540030 (16) [back to overview]Additional Post Op Pain
NCT03540030 (16) [back to overview]Simple Shoulder Test
NCT03540030 (16) [back to overview]Simple Shoulder Test
NCT03540030 (16) [back to overview]Post Op Pain
NCT03540030 (16) [back to overview]Constipation
NCT03540030 (16) [back to overview]Morphine Use
NCT03540030 (16) [back to overview]ASES
NCT03540030 (16) [back to overview]Veterans RAND 12 Item Health Survey (VR-12©) Physical Health Subscore, and Mental Health Subscore
NCT03540030 (16) [back to overview]Pain Satisfaction
NCT03540030 (16) [back to overview]Veterans RAND 12 Item Health Survey (VR-12©) Physical Health Subscore, and Mental Health Subscore
NCT03540030 (16) [back to overview]Pain Satisfaction

Number of Participants Responsive Only to Tactile Stimulation After Anesthesia (Clinical Assessment of Level of Consciousness)

The number of participants responsive only to tactile stimulation was assessed as part of an overall assessment of the clinical level of consciousness by the investigator. The clinical level of consciousness was used as a measure of recovery from NMB at 2 timepoints: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated, 24 hours, or discharged from the hospital if discharge occurs before 24 hours; whichever occurred first. Participants were given a level of consciousness based on what type of stimulation they responded to. Participants who were not cooperative with the examination were not included in the assessment. (NCT00473694)
Timeframe: Up to 24 hours

,,,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium+Neostigmine30
Rocuronium+Sugammadex20
Vecuronium+Neostigmine70
Vecuronium+Sugammadex70

[back to top]

Number of Participants Experiencing General Muscle Weakness

The number of participants experiencing general muscle weakness was assessed by the investigator as a measure of recovery from NMB at 2 timepoints: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessments were performed every 15 minutes until the absence of general muscle weakness. A standardized examination form was used to determine the presence or absence of muscle weakness in various muscle groups. Participants who were not cooperative with the examination were not included in the assessment. (NCT00473694)
Timeframe: Up to 24 hours

,,,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium+Neostigmine53
Rocuronium+Sugammadex32
Vecuronium+Neostigmine23
Vecuronium+Sugammadex41

[back to top]

Number of Participants Aroused With Minimal Stimulation After Anesthesia (Clinical Assessment of Level of Consciousness)

The number of participants aroused with minimal stimulation was assessed as part of an overall assessment of the clinical level of consciousness by the investigator. The clinical level of consciousness was used as a measure of recovery from NMB at 2 timepoints: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated, 24 hours, or discharged from the hospital if discharge occurs before 24 hours; whichever occurred first. Participants were given a level of consciousness based on what type of stimulation they responded to. Participants who were not cooperative with the examination were not included in the assessment. (NCT00473694)
Timeframe: Up to 24 hours

,,,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium+Neostigmine111
Rocuronium+Sugammadex90
Vecuronium+Neostigmine81
Vecuronium+Sugammadex122

[back to top]

Number of Participants Able to Perform a 5-second Head Lift

The number of participants who were able to lift their head for 5 seconds was assessed by the investigator as a measure of recovery from NMB at 2 timepoints: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessment was performed every 15 minutes until the first successful 5-second head lift was achieved. Participants who were not cooperative with the examination were not included in the assessment. (NCT00473694)
Timeframe: Up to 24 hours

,,,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium+Neostigmine2833
Rocuronium+Sugammadex3334
Vecuronium+Neostigmine2433
Vecuronium+Sugammadex3641

[back to top]

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Vecuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.9 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.9. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.9 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 6 hours after administration of study drug

InterventionMinutes (Mean)
Vecuronium+Sugammadex8.73
Vecuronium+Neostigmine77.80

[back to top]

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Rocuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.9 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.9. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.9 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 3 hours after administration of study drug

InterventionMinutes (Mean)
Rocuronium+Sugammadex3.28
Rocuronium+Neostigmine55.50

[back to top]

Number of Participants Awake and Oriented After Anesthesia (Clinical Assessment of Level of Consciousness)

The number of participants who were awake and oriented was assessed as part of an overall assessment of the clinical level of consciousness by the investigator. The clinical level of consciousness was used as a measure of recovery from NMB at 2 timepoints: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated, 24 hours, or discharged from the hospital if discharge occurs before 24 hours; whichever occurred first. Participants were given a level of consciousness based on what type of stimulation they responded to. Participants who were not cooperative with the examination were not included in the assessment. (NCT00473694)
Timeframe: Up to 24 hours

,,,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium+Neostigmine2032
Rocuronium+Sugammadex2634
Vecuronium+Neostigmine2033
Vecuronium+Sugammadex2739

[back to top]

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8 After Neuromuscular Block (NMB) Induced by Vecuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.8 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.8. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.8 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 5 hours after administration of study drug

InterventionMinutes (Mean)
Vecuronium+Sugammadex5.55
Vecuronium+Neostigmine67.42

[back to top]

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8 After Neuromuscular Block (NMB) Induced by Rocuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.8 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.8. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.8 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 3 hours after administration of study drug

InterventionMinutes (Mean)
Rocuronium+Sugammadex2.65
Rocuronium+Neostigmine45.82

[back to top]

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7 After Neuromuscular Block (NMB) Induced by Vecuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.7 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.7. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.7 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 4 hours after administration of study drug

InterventionMinutes (Mean)
Vecuronium+Sugammadex4.10
Vecuronium+Neostigmine56.17

[back to top]

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7 After Neuromuscular Block (NMB) Induced by Rocuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.7 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.7. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.7 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 2 hours after administration of study drug

InterventionMinutes (Mean)
Rocuronium+Sugammadex2.27
Rocuronium+Neostigmine37.68

[back to top]

Time From Start of Administration of Sugammadex or Placebo to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9

Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached >= 0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB. (NCT00552617)
Timeframe: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.9 (up to 24 hours)

InterventionMinutes (Mean)
Rocuronium + Placebo96.30
Rocuronium + 0.5 mg/kg Sugammadex16.30
Rocuronium + 1.0 mg/kg Sugammadex4.62
Rocuronium + 2.0 mg/kg Sugammadex1.43
Rocuronium + 4.0 mg/kg Sugammadex1.50
Vecuronium + Placebo79.02
Vecuronium + 0.5 mg/kg Sugammadex35.50
Vecuronium + 1.0 mg/kg Sugammadex5.07
Vecuronium + 2.0 mg/kg Sugammadex3.42
Vecuronium + 4.0 mg/kg Sugammadex3.03

[back to top]

Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.7

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB. (NCT00552617)
Timeframe: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.7 (up to 24 hours)

InterventionMinutes (Mean)
Rocuronium + Placebo65.67
Rocuronium + 0.5 mg/kg Sugammadex3.08
Rocuronium + 1.0 mg/kg Sugammadex2.08
Rocuronium + 2.0 mg/kg Sugammadex1.12
Rocuronium + 4.0 mg/kg Sugammadex1.02
Vecuronium + Placebo58.12
Vecuronium + 0.5 mg/kg Sugammadex12.57
Vecuronium + 1.0 mg/kg Sugammadex2.35
Vecuronium + 2.0 mg/kg Sugammadex2.00
Vecuronium + 4.0 mg/kg Sugammadex1.70

[back to top]

Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.8

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.8 indicates a faster recovery from NMB. (NCT00552617)
Timeframe: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.8 (up to 24 hours)

InterventionMinutes (Mean)
Rocuronium + Placebo75.85
Rocuronium + 0.5 mg/kg Sugammadex6.25
Rocuronium + 1.0 mg/kg Sugammadex2.62
Rocuronium + 2.0 mg/kg Sugammadex1.28
Rocuronium + 4.0 mg/kg Sugammadex1.15
Vecuronium + Placebo64.33
Vecuronium + 0.5 mg/kg Sugammadex25.65
Vecuronium + 1.0 mg/kg Sugammadex3.10
Vecuronium + 2.0 mg/kg Sugammadex5.83
Vecuronium + 4.0 mg/kg Sugammadex2.12

[back to top]

Duration of Surgery

Time from incision to joint reduction (NCT03219294)
Timeframe: Through study completion, an average of 24 hours for each patient and up to one year for the whole study.

Interventionminutes (Mean)
Moderate NMB32.6
Deep NMB33.8

[back to top]

Percentage of Participants Experiencing an Event of Clinical Interest (ECI) Up To 7 Days After Administration of Study Intervention

As per the protocol primary analysis, the percentage of participants experiencing an ECI up to 7 days after administration of study intervention was reported. ECIs were a discrete set of both AEs and SAEs, specifically designated as such for the trial. For the purposes of this investigation, ECIs included 1) drug-induced liver injury; 2) clinically-relevant arrhythmias, inclusive of bradycardia and tachycardia defined as events necessitating intervention, as determined by investigator judgment; and 3) instances of hypersensitivity and/or anaphylaxis adjudicated by an external expert Adjudication Committee. A participant could have experienced more than one type of ECI. (NCT03346057)
Timeframe: Up to 7 days

,,,
InterventionPercentage of Participants (Number)
With one or more ECIsAdjudicated HypersensitivityAdjudicated AnaphylaxisClinically Relevant BradycardiaClinically Relevant TachycardiaOther Clinically Relevant Cardiac ArrhythmiaDrug Induced Liver Injury
Neostigmine + Glycopyrrolate3.90.00.02.00.02.00.0
Sugammadex 16 mg/kg7.40.00.00.05.91.50.0
Sugammadex 2 mg/kg1.90.00.00.01.90.00.0
Sugammadex 4 mg/kg5.60.00.02.81.90.90.0

[back to top]

Percentage of Participants With Treatment-Emergent Sinus Tachycardia Events

The percentage of participants experiencing treatment-emergent sinus tachycardia events was identified with continuous ECG monitoring. Treatment-emergent sinus tachycardia is defined as a heart rate ≥100 bpm that has also increased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus tachycardia events may or may not have been considered an AE, as determined by investigator judgment. (NCT03346057)
Timeframe: Up to approximately 35 minutes post-administration

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg6.7
Sugammadex 4 mg/kg9.3
Sugammadex 16 mg/kg8.8
Neostigmine + Glycopyrrolate21.6

[back to top]

Percentage of Participants With Other Treatment-Emergent Cardiac Arrhythmia Events

The percentage of participants experiencing other treatment-emergent cardiac arrhythmia events was identified with continuous ECG monitoring. Other treatment-emergent cardiac arrhythmias were defined as new or worsening arrhythmias (e.g., atrial fibrillation, atrial tachycardia, ventricular fibrillation, or ventricular tachyarrhythmia), sustained for at least 1 minute after administration of study intervention. Worsening arrhythmia events may or may not have been considered an AE, as determined by investigator judgment. (NCT03346057)
Timeframe: Up to approximately 35 minutes post-administration

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg1.0
Sugammadex 4 mg/kg0.0
Sugammadex 16 mg/kg1.5
Neostigmine + Glycopyrrolate2.0

[back to top]

Percentage of Participants Experiencing an Adverse Event (AE) Up To 7 Days After Administration of Study Intervention

As per the protocol primary analysis, the percentage of participants experiencing an AE up to 7 days after administration of study intervention was reported. An AE was defined as any untoward medical occurrence in a participant which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. (NCT03346057)
Timeframe: Up to 7 days

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg94.3
Sugammadex 4 mg/kg88.8
Sugammadex 16 mg/kg92.6
Neostigmine + Glycopyrrolate88.2

[back to top]

Percentage of Participants Experiencing a Serious Adverse Event (SAE) Up To 7 Days After Administration of Study Intervention

As per the protocol primary analysis, the percentage of participants experiencing an SAE up to 7 days after administration of study intervention was reported. An SAE was an adverse event that: resulted in death; was life threatening; resulted in persistent or significant disability or incapacity; resulted in or prolonged an existing inpatient hospitalization; was a congenital anomaly or birth defect; was an other important medical event, was a cancer; or was associated with an overdose. (NCT03346057)
Timeframe: Up to 7 days

InterventionPercentage of Participants (Number)
Sugammadex 2 mg/kg11.4
Sugammadex 4 mg/kg7.5
Sugammadex 16 mg/kg10.3
Neostigmine + Glycopyrrolate5.9

[back to top]

Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events

The percentage of participants experiencing treatment-emergent sinus bradycardia events was identified with continuous electrocardiogram (ECG) monitoring. Treatment-emergent sinus bradycardia were defined as a heart rate <60 bpm that has also decreased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus bradycardia events may or may not have been considered an adverse event (AE), as determined by investigator judgment. (NCT03346057)
Timeframe: Up to approximately 35 minutes post-administration

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg1.0
Sugammadex 4 mg/kg1.9
Sugammadex 16 mg/kg7.4
Neostigmine + Glycopyrrolate7.8

[back to top]

Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events

The percentage of participants experiencing treatment-emergent bradycardia events were identified with continuous electrocardiogram (ECG) monitoring. Treatment-emergent sinus bradycardia is defined as a heart rate <60 bpm that has also decreased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus bradycardia events may or may not be considered an adverse event (AE), as determined by investigator judgment. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 35 minutes

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg ABW5.3
Sugammadex 4 mg/kg ABW5.3
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)5.3
Sugammadex 2 mg/kg IBW2.6
Sugammadex 4 mg/kg IBW5.6
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)4.1
Neostigmine/Glycopyrrolate2.6

[back to top]

Percentage of Participants With Treatment-Emergent Sinus Tachycardia Events

The percentage of participants experiencing treatment-emergent sinus tachycardia events were identified with continuous ECG monitoring. Treatment-emergent sinus tachycardia is defined as a heart rate ≥100 bpm that has also increased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus tachycardia events may or may not be considered an AE, as determined by investigator judgment. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 35 minutes

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg ABW10.5
Sugammadex 4 mg/kg ABW13.2
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)11.8
Sugammadex 2 mg/kg IBW7.9
Sugammadex 4 mg/kg IBW2.8
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)5.4
Neostigmine/Glycopyrrolate7.9

[back to top]

Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.7: Geometric Mean Analysis

The efficacy analysis of TTR of participant TOF ratio to ≥0.7 was performed by estimating the geometric mean of TTR within each treatment group. TTR was monitored by applying electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to magnitudes of the first and fourth twitches respectively, after nerve stimulation. The T4/T1 ratio (TOF; expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster TTR of the TOF ratio to 0.7 indicates faster recovery from NMB. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 61 minutes

InterventionMinutes (Geometric Mean)
Sugammadex 2 mg/kg ABW1.4
Sugammadex 4 mg/kg ABW1.3
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)1.4
Sugammadex 2 mg/kg IBW2.1
Sugammadex 4 mg/kg IBW2.0
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)2.1
Neostigmine/Glycopyrrolate10.9

[back to top]

Percentage of Participants Experiencing an Event of Clinical Interest (ECI) After Administration of Study Intervention

The percentage of participants experiencing an ECI following administration of study intervention was monitored. ECIs are a discrete set of both AEs and SAEs, specifically designated as such for the trial. For the purposes of this investigation, ECIs included 1) drug-induced liver injury; 2) clinically-relevant arrhythmias, inclusive of bradycardia and tachycardia defined as events necessitating intervention, as determined by investigator judgment; and 3) instances of hypersensitivity and/or anaphylaxis adjudicated by an external expert Adjudication Committee. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 7 days

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg ABW0.0
Sugammadex 4 mg/kg ABW2.6
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)1.3
Sugammadex 2 mg/kg IBW2.6
Sugammadex 4 mg/kg IBW2.8
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)2.7
Neostigmine/Glycopyrrolate2.6

[back to top]

Time to Recovery (TTR) of Participant Train Of Four (TOF) Ratio to ≥0.9: Primary Kaplan-Meier Analysis

The primary efficacy analysis of TTR of TOF ratio to ≥0.9 was performed by estimating event rates within each treatment group using the Kaplan-Meier method. TTR was monitored by applying electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to magnitudes of the first and fourth twitches respectively, after nerve stimulation. The T4/T1 ratio (TOF; expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster TTR of the TOF ratio to 0.9 indicates faster recovery from NMB. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 76 minutes

InterventionMinutes (Median)
Sugammadex 2 mg/kg ABW1.7
Sugammadex 4 mg/kg ABW1.8
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)1.8
Sugammadex 2 mg/kg IBW3.4
Sugammadex 4 mg/kg IBW3.3
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)3.3
Neostigmine/Glycopyrrolate34.5

[back to top]

Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.9: Secondary Geometric Mean Analysis

The secondary efficacy analysis of TTR of participant TOF ratio to ≥0.9 was performed by estimating the geometric mean of TTR within each treatment group. TTR was monitored by applying electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to magnitudes of the first and fourth twitches respectively, after nerve stimulation. The T4/T1 ratio (TOF; expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster TTR of the TOF ratio to 0.9 indicates faster recovery from NMB. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 76 minutes

InterventionMinutes (Geometric Mean)
Sugammadex 2 mg/kg ABW2.0
Sugammadex 4 mg/kg ABW1.9
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)2.0
Sugammadex 2 mg/kg IBW3.2
Sugammadex 4 mg/kg IBW3.5
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)3.3
Neostigmine/Glycopyrrolate23.1

[back to top]

Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.8: Geometric Mean Analysis

The efficacy analysis of TTR of participant TOF ratio to ≥0.8 was performed by estimating the geometric mean of TTR within each treatment group. TTR was monitored by applying electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to magnitudes of the first and fourth twitches respectively, after nerve stimulation. The T4/T1 ratio (TOF; expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster TTR of the TOF ratio to 0.8 indicates faster recovery from NMB. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 69 minutes

InterventionMinutes (Geometric Mean)
Sugammadex 2 mg/kg ABW1.6
Sugammadex 4 mg/kg ABW1.5
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)1.5
Sugammadex 2 mg/kg IBW2.5
Sugammadex 4 mg/kg IBW2.6
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)2.5
Neostigmine/Glycopyrrolate16.6

[back to top]

Percentage of Participants Experiencing a Serious Adverse Event (SAE) After Administration of Study Intervention

The percentage of participants experiencing an SAE following administration of study intervention was monitored. An SAE is an adverse event that: results in death; is life threatening; results in persistent or significant disability or incapacity; results in or prolongs a hospitalization; is a congenital anomaly or birth defect; is a cancer; or may jeopardize the participant, potentially requiring medical or surgical intervention. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 7 days

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg ABW2.6
Sugammadex 4 mg/kg ABW0.0
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)1.3
Sugammadex 2 mg/kg IBW5.3
Sugammadex 4 mg/kg IBW8.3
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)6.8
Neostigmine/Glycopyrrolate7.9

[back to top]

Percentage of Participants Experiencing an Adverse Event (AE) After Administration of Study Intervention

The percentage of participants experiencing an AE following administration of study intervention was monitored. An AE is any unfavorable and unintended medical occurrence, symptom, or disease witnessed in a participant, regardless of whether or not a causal relationship with the study treatment can be demonstrated. Further, any worsening (i.e. any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study treatment is also considered an AE. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 7 days

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg ABW94.7
Sugammadex 4 mg/kg ABW86.8
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)90.8
Sugammadex 2 mg/kg IBW94.7
Sugammadex 4 mg/kg IBW91.7
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)93.2
Neostigmine/Glycopyrrolate89.5

[back to top]

Percentage of Participants With Other Treatment-Emergent Cardiac Arrhythmia Events

The percentage of participants experiencing other treatment-emergent cardiac arrhythmia events were identified with continuous ECG monitoring. Other treatment-emergent cardiac arrhythmias are defined as new or worsening arrhythmias (e.g., atrial fibrillation, atrial tachyarrhythmia, ventricular fibrillation, or ventricular tachyarrhythmia), sustained for at least 1 minute after administration of study intervention. Worsening arrhythmia events may or may not be considered an AE, as determined by investigator judgment. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 35 minutes

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg ABW0.0
Sugammadex 4 mg/kg ABW0.0
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)0.0
Sugammadex 2 mg/kg IBW2.6
Sugammadex 4 mg/kg IBW0.0
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)1.4
Neostigmine/Glycopyrrolate2.6

[back to top]

Percentage of Participants With Prolonged (>10 Minutes) Time to Recovery (TTR) of the Train Of Four (TOF) Ratio to ≥0.9

Following administration of study intervention, the percentage of participants experiencing prolonged (>10 minutes) recovery to a TOF ratio ≥0.9 was calculated. TTR was monitored by applying electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to magnitudes of the first and fourth twitches respectively, after nerve stimulation. The T4/T1 ratio (TOF; expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster TTR of the TOF ratio to 0.9 indicates faster recovery from NMB. As specified by the protocol, analyses for this outcome measure were conducted in participants pooled by dosing method across depth of NMB (Sugammadex ABW [2 mg/kg ABW plus 4 mg/kg ABW] and Sugammadex IBW [2 mg/kg IBW plus 4 mg/kg IBW]) as well as in all randomized treatment arms separated by depth of NMB (Sugammadex 2 mg/kg ABW, Sugammadex 4 mg/kg ABW, Sugammadex 2 mg/kg IBW, and Sugammadex 4 mg/kg IBW). (NCT03346070)
Timeframe: Up to 76 minutes

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg ABW7.9
Sugammadex 4 mg/kg ABW2.7
Sugammadex ABW (2 mg/kg ABW Plus 4 mg/kg ABW)5.3
Sugammadex 2 mg/kg IBW5.4
Sugammadex 4 mg/kg IBW0.0
Sugammadex IBW (2 mg/kg IBW Plus 4 mg/kg IBW)2.7
Neostigmine/Glycopyrrolate84.2

[back to top]

Nausea

rate of nausea (NCT03540030)
Timeframe: 2 Weeks

,
InterventionParticipants (Count of Participants)
YesNoUnknown
Non-Opioid Intervention1340
Observational5232

[back to top]

Nausea

rate of nausea (NCT03540030)
Timeframe: 2 Months

,
InterventionParticipants (Count of Participants)
YesNoUnknown
Non-Opioid Intervention1300
Observational0282

[back to top]

Falls

rate of falls (NCT03540030)
Timeframe: 2 Weeks

,
InterventionParticipants (Count of Participants)
YesNoUnknown
Non-Opioid Intervention5300
Observational1272

[back to top]

Falls

rate of falls (NCT03540030)
Timeframe: 2 Months

,
InterventionParticipants (Count of Participants)
YesNoUnknown
Non-Opioid Intervention4274
Observational4242

[back to top]

Constipation

rate of constipation (NCT03540030)
Timeframe: 2 Weeks

,
InterventionParticipants (Count of Participants)
YesNoUnknown
Non-Opioid Intervention13220
Observational1992

[back to top]

Additional Post Op Pain

post-operative pain: measured on a 0 (no pain) -10 (worst) numeric rating scale (NRS) at 6hrs, 12hrs, 2 weeks, and 2 months. A score of 0(no pain) is preferable to 10(worst possible pain) (NCT03540030)
Timeframe: 6hrs, 12hrs, 2weeks, 2 months

,
Interventionscore on a scale (Median)
6 Hrs12 hrs2 weeks2 months
Non-Opioid Intervention0.000.820
Observational241.30.7

[back to top]

Simple Shoulder Test

Simple Shoulder Test (SST) activity score. Range 0-12. 0 = worse activity score. (NCT03540030)
Timeframe: 2 Weeks

Interventionscore on a scale (Median)
Observational2.0
Non-Opioid Intervention2.0

[back to top]

Simple Shoulder Test

Simple Shoulder Test (SST) activity score. Range 0-12. 0 = worse activity score. (NCT03540030)
Timeframe: 2 Months

Interventionscore on a scale (Median)
Observational6
Non-Opioid Intervention6

[back to top]

Post Op Pain

Pain at patient discharge or 24-hours, whichever comes first - measured on a 0 (no pain) -10 (worst possible pain) numeric rating scale (NRS). A score of 0(no pain) is preferable to 10(worst possible pain) (NCT03540030)
Timeframe: 24 hours

Interventionscore on a scale (Median)
Observational3.0
Non-Opioid Intervention2.0

[back to top]

Constipation

rate of constipation (NCT03540030)
Timeframe: 2 Months

,
InterventionParticipants (Count of Participants)
YesNoUnknown
Non-Opioid Intervention4274
Observational7212

[back to top]

Morphine Use

Morphine milli-equivalents In-hospital post-operative. Continuous scale of MME, no defined better/worse. Measured as number and dose of medications taken. For example, if the patient received an opioid, the drug and dose was recorded and converted to MME. A time frame of when to assess opioid use in-hospital post-operative was not used but was a continuous monitor for rescue opioid from in-hospital post-operative through discharge. (NCT03540030)
Timeframe: In-hospital Stay

InterventionMorphine milli-equivalents (Median)
Observational45.0
Non-Opioid Intervention19.0

[back to top]

ASES

American Shoulder and Elbow Surgeons (ASES) Shoulder Score for pain and function. Range 0-100. Low score = worse shoulder condition. Function, disability, and pain subscores (all ranges 0-50), and are summed for total ASES score. (NCT03540030)
Timeframe: 2 Weeks

Interventionunits on a scale (Median)
Observational54.3
Non-Opioid Intervention54.2

[back to top]

Veterans RAND 12 Item Health Survey (VR-12©) Physical Health Subscore, and Mental Health Subscore

quality of life using VR-12 subscores. Physical Health (PCS) subscore and Mental Health (MCS) subscore, not summed. Range reported in weighted units. Physical Health subscore: 1 point increase in PCS is associated with 6% lower total health care expenditures, 5% lower pharmacy expenditures, 9% lower rate of hospital inpatient visits, 4% lower rate of medical provider visits, 5% lower rate of hospital outpatient visits. Mental Health sub score a 1 point increase in MCS is associated with 7% lower total health care expenditures, 4% lower pharmacy expenditures, 15% lower rate of hospital inpatient visits, and 4% lower rate of medical provider visits. Both PCS/MCS are score 0-100 with 100 indicating the highest level of health. (NCT03540030)
Timeframe: 2 Months

,
Interventionscore on a scale (Median)
PCSMCS
Non-Opioid Intervention40.360.8
Observational38.458.7

[back to top]

Pain Satisfaction

Satisfaction with overall pain using Numeric Pain Rating (NRS) scale. yes, no. No being better than yes. (NCT03540030)
Timeframe: 2 Weeks

,
InterventionParticipants (Count of Participants)
YesNoUnknown
Non-Opioid Intervention3410
Observational2712

[back to top]

Veterans RAND 12 Item Health Survey (VR-12©) Physical Health Subscore, and Mental Health Subscore

quality of life using VR-12 subscores. Physical Health (PCS) subscore and Mental Health (MCS) subscore, not summed. Range reported in weighted units. Physical Health subscore: 1 point increase in PCS is associated with 6% lower total health care expenditures, 5% lower pharmacy expenditures, 9% lower rate of hospital inpatient visits, 4% lower rate of medical provider visits, 5% lower rate of hospital outpatient visits. Mental Health sub score a 1 point increase in MCS is associated with 7% lower total health care expenditures, 4% lower pharmacy expenditures, 15% lower rate of hospital inpatient visits, and 4% lower rate of medical provider visits. Both PCS/MCS are score 0-100 with 100 indicating the highest level of health. (NCT03540030)
Timeframe: 2 Weeks

,
Interventionscore on a scale (Median)
PCSMCS
Non-Opioid Intervention35.059.1
Observational36.756.3

[back to top]

Pain Satisfaction

Satisfaction with overall pain using Numeric Pain Rating (NRS) scale. yes, no. No being better than yes. (NCT03540030)
Timeframe: 2 Months

,
InterventionParticipants (Count of Participants)
YesNoUnknown
Non-Opioid Intervention2924
Observational2352

[back to top]